



Massachusetts Cannabis Control Commission

Marijuana Retailer

General Information:

License Number: MR282948
Original Issued Date: 09/11/2020
Issued Date: 08/12/2021
Expiration Date: 09/11/2022

ABOUT THE MARIJUANA ESTABLISHMENT

Business Legal Name: Solar Therapeutics Inc.

Phone Number: 508-300-3366 **Email Address:** edward@solarthera.com

Business Address 1: 1400 Brayton Point Rd. **Business Address 2:**

Business City: Somerset **Business State:** MA **Business Zip Code:** 02725

Mailing Address 1: 1400 Brayton Point Rd **Mailing Address 2:**

Mailing City: Somerset **Mailing State:** MA **Mailing Zip Code:** 02725

CERTIFIED DISADVANTAGED BUSINESS ENTERPRISES (DBES)

Certified Disadvantaged Business Enterprises (DBEs): Not a DBE

PRIORITY APPLICANT

Priority Applicant: no

Priority Applicant Type: Not a Priority Applicant

Economic Empowerment Applicant Certification Number:

RMD Priority Certification Number:

RMD INFORMATION

Name of RMD: Solar Therapeutics Inc.

Department of Public Health RMD Registration Number: RMD1205

Operational and Registration Status: Obtained Final Certificate of Registration, but is not open for business in Massachusetts

To your knowledge, is the existing RMD certificate of registration in good standing?: yes

If no, describe the circumstances below:

PERSONS WITH DIRECT OR INDIRECT AUTHORITY

Person with Direct or Indirect Authority 1

Percentage Of Ownership: **Percentage Of Control:** 33.33

Role: Executive / Officer **Other Role:** CEO, COO, President, and Director; Manager of Dow Capital Partners LLC

First Name: Edward **Last Name:** Dow **Suffix:** III

Gender: Male

User Defined Gender:

What is this person's race or ethnicity?: White (German, Irish, English, Italian, Polish, French)

Specify Race or Ethnicity:

Person with Direct or Indirect Authority 2

Percentage Of Ownership: Percentage Of Control: 33.33

Role: Director Other Role: Director, Treasurer

First Name: Ronald Last Name: Rapoport Suffix:

Gender: Male

User Defined Gender:

What is this person's race or ethnicity?: White (German, Irish, English, Italian, Polish, French)

Specify Race or Ethnicity:

Person with Direct or Indirect Authority 3

Percentage Of Ownership: Percentage Of Control: 33.33

Role: Director Other Role: Director, Secretary

First Name: Michael Last Name: Maxim Suffix: II

Gender: Male

User Defined Gender:

What is this person's race or ethnicity?: American Indian or Alaska Native

Specify Race or Ethnicity:

ENTITIES WITH DIRECT OR INDIRECT AUTHORITY

Entity with Direct or Indirect Authority 1

Percentage of Control: 100 Percentage of Ownership: 100

Entity Legal Name: Dow Capital Partners LLC

Entity DBA:

DBA

City:

Entity Description: Dow Capital Partners LLC will fund Solar Therapeutics Inc. in support of its Mission Statement, DBA City: as agreed upon by the Board of Directors

Foreign Subsidiary Narrative:

Entity Phone: Entity Email: Entity Website:

Entity Address 1: Entity Address 2:

Entity City: Entity State: Entity Zip Code:

Entity Mailing Address 1: Entity Mailing Address 2:

Entity Mailing City: Entity Mailing State: Entity Mailing Zip Code:

Relationship Description: Sole shareholder and capital contributor

CLOSE ASSOCIATES AND MEMBERS

Close Associates or Member 1

First Name: Edward Last Name: Dow Suffix: III

Describe the nature of the relationship this person has with the Marijuana Establishment: President and a Director on the Board of Directors; Chief Executive Officer and Chief Operating Officer; Manager of Dow Capital Partners LLC.

Close Associates or Member 2

First Name: Ronald Last Name: Rapoport Suffix:

Describe the nature of the relationship this person has with the Marijuana Establishment: Treasurer and a Director on the Board of Directors

Close Associates or Member 3

First Name: Michael

Last Name: Maxim

Suffix: III

Describe the nature of the relationship this person has with the Marijuana Establishment: Secretary and a Director on the Board of Directors

Close Associates or Member 4

First Name: Robert

Last Name: Keller

Suffix:

Describe the nature of the relationship this person has with the Marijuana Establishment: Chief Financial Officer

CAPITAL RESOURCES - INDIVIDUALS

No records found

CAPITAL RESOURCES - ENTITIES

Entity Contributing Capital 1

Entity Legal Name: Dow Capital Partners LLC

Entity DBA:

Email: edward.dow.iii@gmail.com Phone: 603-498-6326

Address 1: 1400 Brayton Point Rd

Address 2:

City: SOMERSET

State: MA

Zip Code: 02725

Types of Capital: Monetary/Equity Other Type of Capital: Total Value of Capital Provided: \$300000 Percentage of Initial Capital: 100

Capital Attestation: Yes

BUSINESS INTERESTS IN OTHER STATES OR COUNTRIES

No records found

DISCLOSURE OF INDIVIDUAL INTERESTS

No records found

MARIJUANA ESTABLISHMENT PROPERTY DETAILS

Establishment Address 1: 1735 Fall River Avenue

Establishment Address 2:

Establishment City: Seekonk

Establishment Zip Code: 02771

Approximate square footage of the establishment: 1650 How many abutters does this property have?: 11

Have all property abutters been notified of the intent to open a Marijuana Establishment at this address?: Yes

HOST COMMUNITY INFORMATION

Host Community Documentation:

Document Category	Document Name	Type	ID	Upload Date
Certification of Host Community Agreement	Seekonk Host Community Agreement Cert Form - Aug 22 2019 - 3-28 PM.pdf	pdf	5d7276f8816d7b225d159172	09/06/2019
Community Outreach Meeting Documentation	Community-Outreach-Meeting-Attestation-Form SEEKONK.pdf	pdf	5d7277e7af9d6f1dd58a22c0	09/06/2019
Plan to Remain Compliant with Local Zoning	SOLAR THERA Plan to Remain Compliant With Zoning_Seekonk.pdf	pdf	5d7278a332375f1de7f6e575	09/06/2019

Total amount of financial benefits accruing to the municipality as a result of the host community agreement. If the total amount is zero, please enter zero and provide documentation explaining this number.: \$1

PLAN FOR POSITIVE IMPACT

Plan to Positively Impact Areas of Disproportionate Impact:

Document Category	Document Name	Type	ID	Upload Date
Plan for Positive Impact	SOP Plan for Positive Impact.pdf	pdf	5e457b927225f0046965906c	02/13/2020

ADDITIONAL INFORMATION NOTIFICATION

Notification: I understand

INDIVIDUAL BACKGROUND INFORMATION

Individual Background Information 1

Role: Other Role:
 First Name: Edward Last Name: Dow Suffix: III
 RMD Association: RMD Owner
 Background Question: no

Individual Background Information 2

Role: Other Role:
 First Name: Ronald Last Name: Rapoport Suffix:
 RMD Association: RMD Owner
 Background Question: no

Individual Background Information 3

Role: Other Role:
 First Name: Michael Last Name: Maxim Suffix: II
 RMD Association: RMD Owner
 Background Question: no

Individual Background Information 4

Role: Other Role:
 First Name: Robert Last Name: Keller Suffix:
 RMD Association: RMD Manager
 Background Question: no

ENTITY BACKGROUND CHECK INFORMATION

Entity Background Check Information 1

Role: Investor/Contributor Other Role:
 Entity Legal Name: Dow Capital Partners LLC Entity DBA:
 Entity Description: Funding entity for Solar Therapeutics Inc.
 Phone: 603-498-6326 Email: edward.dow.iii@gmail.com
 Primary Business Address 1: 1400 Brayton Point Road Primary Business Address 2:
 Primary Business City: Somerset Primary Business State: MA Principal Business Zip Code: 02725
 Additional Information:

MASSACHUSETTS BUSINESS REGISTRATION

Required Business Documentation:

Document Category	Document Name	Type	ID	Upload Date
Articles of Organization	Solar_APP_MOP_2_Certificate-of-Entity-	pdf	5d5da4a17e918b22a66bd708	08/21/2019

Conversion.pdf				
Bylaws	Solar_APP_MOP_3_For_Profit_Bylaws.pdf	pdf	5d5da4a3d8b08e1dbf142327	08/21/2019
Secretary of Commonwealth - Certificate of Good Standing	Cert.GoodstandingSecretarycommonwealth.pdf	pdf	5e45857a4fa2b004756a1d8e	02/13/2020
Department of Revenue - Certificate of Good standing	MA Tax Conn Cert of Good Standing 12.31.19 (1).pdf	pdf	5e45857c64339304b08ff5e7	02/13/2020

Certificates of Good Standing:

Document Category	Document Name	Type	ID	Upload Date
Secretary of Commonwealth - Certificate of Good Standing	Sec of State Good Standing 6.17.21.pdf	pdf	60e48ac174b6080359f6f5a0	07/06/2021
Department of Revenue - Certificate of Good standing	DOR Cert of Good Standing 6.21.21.pdf	pdf	60e48ac7629ad9037af1e988	07/06/2021
Department of Unemployment Assistance - Certificate of Good standing	Certificate of Compliance Unemployment.pdf	pdf	60e48acd7a4b3b034a67f780	07/06/2021

Massachusetts Business Identification Number: 001339748

Doing-Business-As Name:

DBA Registration City:

BUSINESS PLAN

Business Plan Documentation:

Document Category	Document Name	Type	ID	Upload Date
Business Plan	seekonk business plan.pdf	pdf	5d5da4bf629a272281d2f303	08/21/2019
Plan for Liability Insurance	Solar_APP_MOP_5_Plan for Liability Insurance.pdf	pdf	5d5da5547e918b22a66bd710	08/21/2019
Proposed Timeline	Seekonk Timeline renewal update.pdf	pdf	60ec682b84f3fe0296c420a3	07/12/2021

OPERATING POLICIES AND PROCEDURES

Policies and Procedures Documentation:

Document Category	Document Name	Type	ID	Upload Date
Separating recreational from medical operations, if applicable	SOP Plan for Separating Recreational from Medical Operations.pdf	pdf	5e45bac27b9883042b37249a	02/13/2020
Security plan	Solar Security Plan-Seekonk Revised 02.2020.pdf	pdf	5e541d31d43df3043d4bb365	02/24/2020
Plan for obtaining marijuana or marijuana products	Plan for Obtaining Marijuana or Marijuana Products Seekonk.pdf	pdf	60e4914caa87100331f631e5	07/06/2021
Restricting Access to age 21 and older	Plan for Restricting Access to Age 21 and Older Seekonk.pdf	pdf	60e4917f1159b60338d4ceb1	07/06/2021
Prevention of diversion	Plan for Prevention of Diversion Seekonk.pdf	pdf	60e491b9fb983a0274aac08e	07/06/2021
Storage of marijuana	Plan for Storage of Marijuana Seekonk.pdf	pdf	60e491ed84f3fe0296c40937	07/06/2021

Transportation of marijuana	Plan for Transportation of Marijuana Seekonk.pdf	pdf	60e4921074b6080359f6f608	07/06/2021
Inventory procedures	Plan for Inventory Procedures Seekonk.pdf	pdf	60e4923523f3f9033f374d2f	07/06/2021
Quality control and testing	Plan for Quality Control and Testing Seekonk.pdf	pdf	60e49253629ad9037af1e9ec	07/06/2021
Dispensing procedures	Plan for Dispensing Procedures Seekonk.pdf	pdf	60e4927374b6080359f6f60e	07/06/2021
Record Keeping procedures	Plan for Recordkeeping Procedures Seekonk.pdf	pdf	60e4929b629ad9037af1e9f4	07/06/2021
Maintaining of financial records	Plan for Maintaining of Financial Records Seekonk.pdf	pdf	60e492c084f3fe0296c4093f	07/06/2021
Qualifications and training	Plan for Qualifications and Training Procedures Seekonk.pdf	pdf	60e492e5ddf0e402a870d3c1	07/06/2021
Personnel policies including background checks	Plan for Personnel Policies Including Background Checks Seekonk.pdf	pdf	60e7416a84f3fe0296c41410	07/08/2021
Energy Compliance Plan	2021_0123 Solar Therapeutics - Seekonk Dispensary Final CD's Issued Forpdf	pdf	60e74ae31159b60338d4da75	07/08/2021
Energy Compliance Plan	Seekonk Dispensary Energy Compliance.pdf	pdf	60e74af52ea73e036476b321	07/08/2021
Diversity plan	Solar Diversity Plan.pdf	pdf	60e8968484f3fe0296c419a1	07/09/2021

MARIJUANA RETAILER SPECIFIC REQUIREMENTS

No documents uploaded

No documents uploaded

ATTESTATIONS

I certify that no additional entities or individuals meeting the requirement set forth in 935 CMR 500.101(1)(b)(1) or 935 CMR 500.101(2)(c)(1) have been omitted by the applicant from any marijuana establishment application(s) for licensure submitted to the Cannabis Control Commission.: I Agree

I understand that the regulations stated above require an applicant for licensure to list all executives, managers, persons or entities having direct or indirect authority over the management, policies, security operations or cultivation operations of the Marijuana Establishment; close associates and members of the applicant, if any; and a list of all persons or entities contributing 10% or more of the initial capital to operate the Marijuana Establishment including capital that is in the form of land or buildings.: I Agree

I certify that any entities who are required to be listed by the regulations above do not include any omitted individuals, who by themselves, would be required to be listed individually in any marijuana establishment application(s) for licensure submitted to the Cannabis Control Commission.: I Agree

Notification: I Understand

I certify that any changes in ownership or control, location, or name will be made pursuant to a separate process, as required under 935 CMR 500.104(1), and none of those changes have occurred in this application.: I Agree

I certify that to the best knowledge of any of the individuals listed within this application, there are no background events that have arisen since the issuance of the establishment's final license that would raise suitability issues in accordance with 935 CMR 500.801.: I Agree

I certify that all information contained within this renewal application is complete and true.: I Agree

ADDITIONAL INFORMATION NOTIFICATION

Notification: I Understand

COMPLIANCE WITH POSITIVE IMPACT PLAN

Progress or Success Goal 1

Description of Progress or Success: Solar Therapeutics has yet to receive a final license and commence operations in Seekonk. Solar's plan to positively impact areas of disproportionate impact is included below.

COMPLIANCE WITH DIVERSITY PLAN

Diversity Progress or Success 1

Description of Progress or Success: Solar Therapeutics is currently in the process of listing job openings and interviewing applicants for positions at the Seekonk retail location.

HOURS OF OPERATION

Monday From: 9:00 AM	Monday To: 9:00 PM
Tuesday From: 9:00 AM	Tuesday To: 9:00 PM
Wednesday From: 9:00 AM	Wednesday To: 9:00 PM
Thursday From: 9:00 AM	Thursday To: 9:00 PM
Friday From: 9:00 AM	Friday To: 9:00 PM
Saturday From: 9:00 AM	Saturday To: 9:00 PM
Sunday From: 11:00 AM	Sunday To: 5:00 PM

Host Community Agreement Certification Form

The applicant and contracting authority for the host community must complete each section of this form before uploading it to the application. Failure to complete a section will result in the application being deemed incomplete. Instructions to the applicant and/or municipality appear in italics. Please note that submission of information that is “misleading, incorrect, false, or fraudulent” is grounds for denial of an application for a license pursuant to 935 CMR 500.400(1).

Applicant


I, EDWARD F. DOW III, (*insert name*) certify as an authorized representative of SOLAR THERAPEUTICS (*insert name of applicant*) that the applicant has executed a host community agreement with SEEKONK (*insert name of host community*) pursuant to G.L.c. 94G § 3(d) on AUG 22, 2019 (*insert date*).



Signature of Authorized Representative of Applicant

Host Community

I, Shawn E. Cadime, (*insert name*) certify that I am the contracting authority or have been duly authorized by the contracting authority for Town of Seekonk (*insert name of host community*) to certify that the applicant and Town of Seekonk (*insert name of host community*) has executed a host community agreement pursuant to G.L.c. 94G § 3(d) on August 22, 2019 (*insert date*).



Town Administrator
Signature of Contracting Authority or
Authorized Representative of Host Community

Community Outreach Meeting Attestation Form

The applicant must complete each section of this form and initial each page before uploading it to the application. Failure to complete a section will result in the application being deemed incomplete. Instructions to the applicant appear in italics. Please note that submission of information that is “misleading, incorrect, false, or fraudulent” is grounds for denial of an application for a license pursuant to 935 CMR 500.400(1).

I, EDWARD DOW, (*insert name*) attest as an authorized representative of SOLAR THERAPEUTICS, INC. (*insert name of applicant*) that the applicant has complied with the requirements of 935 CMR 500 and the guidance for licensed applicants on community outreach, as detailed below.

1. The Community Outreach Meeting was held on SEPTEMBER 3, 2019 (*insert date*).
2. A copy of a notice of the time, place, and subject matter of the meeting, including the proposed address of the Marijuana Establishment, was published in a newspaper of general circulation in the city or town on AUGUST 26, 2018 (*insert date*), which was at least seven calendar days prior to the meeting. A copy of the newspaper notice is attached as Attachment A (*please clearly label the newspaper notice in the upper right hand corner as Attachment A and upload it as part of this document*).
3. A copy of the meeting notice was also filed on AUGUST 22, 2019 (*insert date*) with the city or town clerk, the planning board, the contracting authority for the municipality, and local licensing authority for the adult use of marijuana, if applicable. A copy of the municipal notice is attached as Attachment B (*please clearly label the municipal notice in the upper right-hand corner as Attachment B and upload it as part of this document*).
4. Notice of the time, place and subject matter of the meeting, including the proposed address of the Marijuana Establishment, was mailed on AUGUST 22, 2019 (*insert date*), which was at least seven calendar days prior to the community outreach meeting to abutters of the proposed address of the Marijuana Establishment, and residents within 300 feet of the property line of the petitioner as they appear on the most recent applicable tax list, notwithstanding that the land of any such owner is located in another city or town. A copy of one of the notices sent to abutters and parties of interest as described in this section is attached as Attachment C (*please clearly label the municipal notice in the upper right hand corner as Attachment C and upload it as part of this document; please only include a copy of one notice and please black out the name and the address of the addressee*).

5. Information was presented at the community outreach meeting including:
 - a. The type(s) of Marijuana Establishment to be located at the proposed address;
 - b. Information adequate to demonstrate that the location will be maintained securely;
 - c. Steps to be taken by the Marijuana Establishment to prevent diversion to minors;
 - d. A plan by the Marijuana Establishment to positively impact the community; and
 - e. Information adequate to demonstrate that the location will not constitute a nuisance as defined by law.

6. Community members were permitted to ask questions and receive answers from representatives of the Marijuana Establishment.



1400 Brayton Point Rd.
Somerset, MA 02725

B6 The Sun Chronicle ■ Monday, August 26, 2019

To place an ad, log on to
thesunchronicle.com/admarket
and click place an ad
508-222-7018
Fax: 508-236-0463

CLAS

LEGALS

Community Outreach Meeting

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for **September 3, 2019 at 3:00 p.m.** at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. **The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771.** There will be an opportunity for the public to ask questions.
08/26/2019

LEGALS

Covel Ave



**TOWN OF SEEKONK
ZONING BOARD OF APPEALS
PUBLIC HEARING NOTICE**

In accordance with Chapter 40A of the General Laws, and Town of Seekonk Zoning By-Laws, a Public Hearing will held at the Town Hall, 100 Peck Street in Seekonk, MA **Monday, September 9, 2019** in the Town Hall Meeting Room beginning at 7:00 P.M. to hear the following petitions:

2019-09 Colt & Meganne Duckworth, 31 Covel Ave Seekonk, MA, owners and petitioners, requesting a Special Permit under section 4.3.2 of the Town of Seekonk zoning bylaws to allow the construction of a 20x20 garage on a lawfully, nonconforming lot located at 31 Covel Avenue, Plat 34, Lots 75 & 76 in the R-1 zone and containing a total of 10,070 sq. ft.

2019-10 Colt & Meganne Duckworth, 31 Covel Ave Seekonk, MA, owners and petitioners, requesting a Variance under section 5.2 of the Town of Seekonk zoning bylaw to allow the construction of a 20x20 garage within the rear setback of a lawfully, nonconforming lot located at 31 Covel Avenue, Plat 34, Lots 75 & 76 in the R-1 zone and containing a total of 10,070 sq. ft.

2019-11 Colt & Meganne Duckworth, 31 Covel Ave Seekonk, MA, owners and petitioners, requesting a Variance under section 5.2 of the Town of Seekonk zoning bylaw to allow the construction of a 20x20 garage within the side setback of a lawfully, nonconforming lot located at 31 Covel Avenue, Plat 34, Lots 75 & 76 in the R-1 zone and containing a total of 10,070 sq. ft.

LEGALS

Oak Drive

NOTICE OF MORTGAGEE'S SALE OF REAL ESTATE

By virtue and in execution of the Power of Sale contained in a certain mortgage given by Gayle A Workman, Hamilton Workman to CitiMortgage, Inc., dated March 23, 2005 and recorded in the Norfolk County Registry of Deeds in Book 22217, Page 515, of which mortgage the undersigned is the present holder, for breach of the conditions of said mortgage and for the purpose of foreclosing, the same will be sold at Public Auction at 5:00 PM on September 24, 2019, on the mortgaged premises located at 1 Oak Drive, Plainville, Norfolk County, Massachusetts, all and singular the premises described in said mortgage,

TO WIT:

The land at One Oak Drive, Plainville, Norfolk County, Massachusetts being shown as Lot 52 on a Plan entitled 'Sectoin Three, Highland Meadows Park, Plainville, mass.', dated June 1962 by the W.T. Whalen Engineering Co., Owned by Plainville Realty Trust, recorded with Norfolk County Registry of Deeds, Plan Book 218, Plan 780. Said Premises are subject to the following encumbrances: 1. Rights of others in streets and ways shown on the above-mentioned plan. 2. Easement to Massachusetts Electric Company, et al





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

FLORICE CRAIG
SEEKONK TOWN CLERK
100 PECK STREET
SEEKONK, MA 02771

Subject: Community Outreach Public Notice

Dear Mrs. Craig,

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

JOHN J. AUBIN III
SEEKONK TOWN PLANNER
100 PECK STREET
SEEKONK, MA 02771

Subject: Community Outreach Public Notice

Dear Mr. Aubin,

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

SHAWN E. CADIME
SEEKONK TOWN ADMINISTRATOR
100 PECK STREET
SEEKONK, MA 02771

Subject: Community Outreach Public Notice

Dear Mr. Cadime,

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

DAVID ANDRADE
CHAIRMAN, SEEKONK BOARD OF SELECTMEN
151 ALLEN AVENUE
SEEKONK, MA 02771

Subject: Community Outreach Public Notice

Dear Chairman Andrade,

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

RTKL 708(b)(11)

Subject: Community Outreach Public Notice

Dear RTKL 708(b)(11)

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

RTKL 708(b)(11)

Subject: Community Outreach Public Notice

Dear RTKL 708(b)(11)

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

RTKL 708(b)(11)

Subject: Community Outreach Public Notice

Dear RTKL 708(b)(11)

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.





1400 Brayton Point Rd.
Somerset, MA 02725

August 22, 2019

RTKL 708(b)(11)

Subject: Community Outreach Public Notice

Dear RTKL 708(b)(11)

Notice is hereby given that a Community Outreach Meeting for a proposed Marijuana Establishment is scheduled for September 3, 2019 at 3:00 p.m. at the Clarion Inn Providence-Seekonk at 940 Fall River Avenue, Seekonk, MA 02771. The proposed Marijuana Dispensary is anticipated to be located at 1735 Fall River Avenue, Seekonk, MA 02771. There will be an opportunity for the public to ask questions.

Sincerely,

Edward Dow III

President , Solar Therapeutics Inc.



Plan to Remain Compliant with Local Zoning

Solar Therapeutics Inc. (“Solar Thera”) will remain compliant at all times with the local zoning requirements set forth in the Town of Seekonk Zoning By-Law. In accordance with Zoning By-Law Section 6.10.3.2, Solar Thera’s proposed marijuana retailer facility is located in an AED & MOD designated zone for retailer marijuana establishments.

In compliance with 935 CMR 500.110(3), the property is not located within 500 feet of any public or private school providing education in kindergarten or any of grades 1 through 12.

Additionally, and in compliance with Seekonk Zoning By-Law Section 6.10.3.2, Solar Thera’s proposed site is not located within 1,000 feet of the following:

- (i) School, including a public or private elementary, vocational, or secondary school or a public or private college, junior college, or university;
- (ii) Child Care Facility;
- (iii) Library;
- (iv) Playground;
- (v) Public Park;
- (vi) Youth center;
- (vii) Public swimming pool
- (viii) Video arcade facility; or
- (ix) Similar facility in which minors commonly congregate.





June 25, 2021

Town of Seekonk
Attn: Shawn E. Cadime
Town Administrator
100 Peck Street
Seekonk, MA 02771

Dear Mr. Cadime,

As you may know, Solar Therapeutics will soon commence retail operations in Seekonk. We are communicating with you to inquire about any possible expenses incurred due to the operations of Solar Therapeutics within the municipality of Seekonk. In accordance with M.G.L. c. 94G, SS 3(d), any cost to a city or town imposed by the operation of a Marijuana Establishment or MTC shall be documented and considered a public record as defined by M.G.L. c. 4, ss 7, cl. 26.

Please relay any possible expenses associated with our operations within Seekonk.

Feel free to reach out to me directly with any feedback or questions.

Sincerely,

A handwritten signature in black ink, appearing to read "Robert L. Keller", written in a cursive style.

Robert L. Keller
Chief Financial Officer
603-801-5342
Rkeller@solarthera.com

CC: Massachusetts Cannabis Control Commission



July 2, 2021

To Whom It May Concern,

I, Robert L. Keller, CFO of Solar Therapeutics, do here by attest that we have not yet received a response from the Town of Seekonk in relation to the letter dated June 25, 2021 requesting any information related to any expenses the town may have incurred due to the operations of Solar Therapeutics, Inc.

Please do not hesitate to reach out to me directly with any questions.

Sincerely,

A handwritten signature in black ink, appearing to read "Robert L. Keller", written in a cursive style.

Robert L. Keller
Solar Therapeutics
Chief Financial Officer
603-801-5342
RKeller@solarthera.com



June 25, 2021

To Whom It May Concern,

According to our records, we, Solar Therapeutics, have not opened at the Seekonk location nor sold any marijuana products to date. Once we commence, Solar will maintain proper books and records and document all marijuana sales and record 3% of the marijuana sales for the given period and forward to the Town of Seekonk per the Host Community Agreement (HCA).

If you require any additional information, please feel free to contact me directly.

Sincerely,

A handwritten signature in black ink, appearing to read "Robert L. Keller", written in a cursive style.

Robert L. Keller
Solar Therapeutics
Chief Financial Officer
603-801-5342
RKeller@solarthera.com



July 2, 2021

To Whom It May Concern,

I, Robert L. Keller, CFO of Solar Therapeutics, do here by attest that we have not yet received a response from the Town of Seekonk in relation to the letter dated June 25, 2021 requesting any information related to any expenses the town may have incurred due to the operations of Solar Therapeutics, Inc.

Please do not hesitate to reach out to me directly with any questions.

Sincerely,

A handwritten signature in black ink, appearing to read "R. L. Keller".

Robert L. Keller
Solar Therapeutics
Chief Financial Officer
603-801-5342
RKeller@solarthera.com

Plan for Positive Impact

Overview

Solar Therapeutics, Inc. (“Solar Thera”) is dedicated to serving and supporting populations falling within areas of disproportionate impact, which the Commission has identified as the following:

1. Past or present residents of the geographic “areas of disproportionate impact,” which have been defined by the Commission and identified in its Guidance for Identifying Areas of Disproportionate Impact;
2. Commission-designated Economic Empowerment Priority applicants;
3. Commission-designated Social Equity Program participants;
4. Massachusetts residents who have past drug convictions; and
5. Massachusetts residents with parents or spouses who have drug convictions are classified as areas of disproportionate impact.

To support such populations, Solar Thera has created the following Plan to Positively Impact Areas of Disproportionate Impact (the “Plan”) and has identified and created goals/programs to positively impact Taunton and Fall River.

Goals

In order for Solar Thera to positively impact Taunton and Fall River, Solar Thera has established the following goals:

1. To provide continuing service and reinvestment into the identified areas of disproportionate impact through workforce development; and
2. To reduce the barrier to entry in the commercial adult use cannabis industry.

Programs

Solar Thera has developed specific programs to effectuate its stated goals to positively impact Taunton and Fall River. Such programs will include the following:

1. Prioritize the hiring of individuals from our identified areas of disproportionate impact;
2. Conducting at least four one-hour industry-specific educational seminars annually across one or more of the following topics: marijuana cultivation, marijuana product manufacturing, marijuana retailing, or marijuana business training; and
3. Holding at least one annual informational session regarding the process for sealing and expunging criminal records.

Measurements

The Chief Operating Officer (“COO”) will administer the Plan and will be responsible for developing measurable outcomes to ensure Solar Thera continues to meet its commitments. Such measurable outcomes, in accordance with Solar Thera’s goals and programs described above will include:

1. Documentation and monitoring of the number of employees hired, retained or promoted that come from areas of disproportionate impact (Solar Thera will hire at least 10% of their employees from areas of disproportionate impact);
2. Documentation of the agendas, presentation material, and handouts that will be available at the seminars;
3. Documentation of the newspaper and social media advertisements of the seminars; and
4. Documentation and tracking of seminar attendance levels;

The COO will review and evaluate Solar Thera’s measurable outcomes no less than annually to ensure that Solar Thera is meeting its commitments. Solar Thera is mindful that demonstration of the Plan’s progress and success will be submitted to the Commission upon renewal.

Acknowledgements

- Solar Thera will adhere to the requirements set forth in 935 CMR 500.105(4) which provides the permitted and prohibited advertising, branding, marketing, and sponsorship practices of every Marijuana Establishment.
- Any actions taken, or programs instituted, by Solar Thera will not violate the Commission’s regulations with respect to limitations on ownership or control or other applicable state laws.

D

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

DO NOT BE TYPED

Articles of Entity Conversion of a Domestic Non-Profit with a Pending Provisional or Final Certification to Dispense Medical Use Marijuana to a Domestic Business Corporation (General Laws Chapter 156D, Section 9.53; 950 CMR 113.30)

FORM M

Solar Therapeutics, Inc. is a registrant with the Department of Public Health in accordance with 105 CMR 725.100(C) as of August 1, 2018.

Elizabeth Chen, PhD
Interim Director
Bureau of Health Care Safety and Quality
Massachusetts Department of Public Health

(1) Exact name of the non-profit: Solar Therapeutics Inc.

001302432

(2) A corporate name that satisfies the requirements of G.L. Chapter 156D, Section 4.01:

Solar Therapeutics Inc.

(3) The plan of entity conversion was duly approved in accordance with the law.

(4) The following information is required to be included in the articles of organization pursuant to G.L. Chapter 156D, Section 2.02(a) or permitted to be included in the articles pursuant to G.L. Chapter 156D, Section 2.02(b):

ARTICLE I

The exact name of the corporation upon conversion is:

Solar Therapeutics Inc.

ARTICLE II

Unless the articles of organization otherwise provide, all corporations formed pursuant to G.L. Chapter 156D have the purpose of engaging in any lawful business. Please specify if you want a more limited purpose:*

The corporation is organized: (a) to cultivate, manufacture, market, promote, sell, distribute and otherwise provide products containing cannabis, products that enable persons to consume cannabis in different forms, and other related products, for medicinal uses, but only in accordance with the laws of the Commonwealth of Massachusetts; (b) to engage in all activities incidental thereto; and (c) to engage in any other activities in which a corporation formed under the laws of the Commonwealth of Massachusetts may lawfully engage.

5
PC.

ARTICLE III

State the total number of shares and par value, * if any, of each class of stock that the corporation is authorized to issue. All corporations must authorize stock. If only one class or series is authorized, it is not necessary to specify any particular designation.

WITHOUT PAR VALUE		WITH PAR VALUE		
TYPE	NUMBER OF SHARES	TYPE	NUMBER OF SHARES	PAR VALUE
Common	240,000			

ARTICLE IV

Prior to the issuance of shares of any class or series, the articles of organization must set forth the preferences, limitations and relative rights of that class or series. The articles may also limit the type or specify the minimum amount of consideration for which shares of any class or series may be issued. Please set forth the preferences, limitations and relative rights of each class or series and, if desired, the required type and minimum amount of consideration to be received.

Holders of Common Stock shall be entitled to one (1) vote for each share of Common Stock. Any holder of shares entitled to vote on any matter may vote part of such shares in favor of the proposal and refrain from voting the remaining shares or vote them against the proposal. If a stockholder fails to specify the number of shares such stockholder is voting affirmatively, it will be conclusively presumed that the stockholder's approving vote is with respect to all shares such stockholder is entitled to vote.

ARTICLE V

The restrictions, if any, imposed by the articles or organization upon the transfer of shares of any class or series of stock are:

ARTICLE VI

Other lawful provisions, and if there are no such provisions, this article may be left blank.

See Article VI Continuation Sheet

Note: The preceding six (6) articles are considered to be permanent and may be changed only by filing appropriate articles of amendment.

ARTICLE VI: CONTINUATION SHEET

1. **Limitation of Director Liability.** Except as required by applicable law, no Director of the corporation shall have any personal liability to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. The preceding sentence shall not eliminate or limit the liability of a director for any act or omission occurring prior to the date upon which such provision becomes effective.
2. **Indemnification.** The Corporation shall, to the extent permitted by G.L. c. 156D, indemnify all persons who have served or may serve at any time as officers or Directors of the Corporation and their heirs, executors, administrators, successors, and assigns, from and against any and all loss and expense, including amounts paid in settlement before or after suit is commenced, and reasonable attorney's fees, actually and necessarily incurred as a result of any claim, demand, action, proceeding, or judgment that may have been asserted against any such persons, or in which these persons are made parties by reason of their being or having been officers or Directors of the Corporation. This right of indemnification shall not exist in relation to matters as to which it is adjudged in any action, suit or proceeding that these persons are liable for negligence or misconduct in the performance of duty. The indemnification rights provided herein (i) shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any law, agreement, vote of shareholders or otherwise; and (ii) shall inure to the benefit of the heirs, executors and administrators of such persons entitled to indemnification. The Corporation may, to the extent authorized from time to time by the board of Directors, grant indemnification rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth herein.
3. **Partnership.** The Corporation may be a partner to the maximum extent permitted by law.
4. **Shareholder Action Without a Meeting by Less Than Unanimous Consent.** Any action that, under any provision of G.L. c. 156D may be taken at a meeting of the shareholders, may be taken without a meeting and without prior notice if a consent in writing, setting forth the action so taken, shall be signed by the holders of the outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares are entitled to vote thereon were present and voted; provided, however, that unless the consents of all shareholders entitled to vote have been solicited in writing, notice shall be given (in the same manner as notice of meetings is to be given), and within the time limits prescribed by law, of such action to all shareholders entitled to vote who did not consent in writing to such action; and provided, further, that Directors may be elected by written consent only if such consent is given by shareholders holding eighty-five percent (85%) of the outstanding votes held by shareholders, except that action taken by shareholders to fill one or more vacancies on the board other than a vacancy created by the removal of a Director, may be taken by written consent of a majority of the outstanding shares entitled to vote.
5. **Authorization of Directors to Make, Amend or Repeal Bylaws.** The board of directors may make, amend or repeal the Bylaws in whole or in part, except with respect to any provision thereof which by virtue of an express provision in Chapter 156D of the General Laws of Massachusetts, the Articles of Organization or the Bylaws requires action by the shareholders.

ARTICLE VII

The effective date of organization of the corporation is the date and time the articles were received for filing if the articles are not rejected within the time prescribed by law. If a later effective date is desired, specify such date, which may not be later than the 90th day after the articles are received for filing:

ARTICLE VIII

The information contained in this article is not a permanent part of the articles of organization.

- a. The street address of the initial registered office of the corporation in the commonwealth:
1400 Brayton Point Road Somerset, MA 02725
- b. The name of its initial registered agent at its registered office:
Edward Dow III
- c. The names and addresses of the individuals who will serve as the initial directors, president, treasurer and secretary of the corporation (an address need not be specified if the business address of the officer or director is the same as the principal office location):

President: Edward Dow III

Treasurer: Ronald Rapoport

Secretary: Michael Maxim

Director(s): Edward Dow III, Ronald Rapoport, Michael Maxim

- d. The fiscal year end of the corporation:
December 31
- e. A brief description of the type of business in which the corporation intends to engage:
Cultivate, manufacture, market, promote, sell and distribute medicinal cannabis and related products.
- f. The street address of the principal office of the corporation:
1400 Brayton Point Road Somerset, MA 02725
- g. The street address where the records of the corporation required to be kept in the commonwealth are located is:

1400 Brayton Point Road Somerset, MA 02725, which is
(number, street, city or town, state, zip code)

- its principal office;
- an office of its transfer agent;
- an office of its secretary/assistant secretary;
- its registered office.



Signed by: _____

(signature of authorized individual)

- Chairman of the board of directors,
- President,
- Other officer,
- Court-appointed fiduciary,

on this 16th day of July, 2018

SECRETARY OF THE
COMMONWEALTH

COMMONWEALTH OF MASSACHUSETTS

2018 AUG -2 PM 3:48

CORPORATIONS DIVISION

William Francis Galvin
Secretary of the Commonwealth
One Ashburton Place, Boston, Massachusetts 02108-1512

**Articles of Entity Conversion of a
Domestic Non-Profit with a Pending Provisional or
Final Certification to Dispense Medical Use Marijuana
to a Domestic Business Corporation**
(General Laws Chapter 156D, Section 9.53; 950 CMR 113.30)

I hereby certify that upon examination of these articles of conversion, duly submitted to me, it appears that the provisions of the General Laws relative thereto have been complied with, and I hereby approve said articles; and the filing fee in the amount of \$ 475 having been paid, said articles are deemed to have been filed with me this 2 day of August, 20 18, at _____ a.m./p.m.
time

Effective date: _____
(must be within 90 days of date submitted)



WILLIAM FRANCIS GALVIN
Secretary of the Commonwealth

1081

Examiner DB

Name approval

Filing fee: Minimum \$250

TO BE FILLED IN BY CORPORATION
Contact Information:

C

M

Solar Therapeutics Inc.

1400 Brayton Point Road

Somerset, MA 02725

Telephone: (603) 498-6326

Email: edward.dow.iii@gmail.com

Upon filing, a copy of this filing will be available at www.sec.state.ma.us/cor. If the document is rejected, a copy of the rejection sheet and rejected document will be available in the rejected queue.

1315007

**BYLAWS
OF
SOLAR THERAPEUTICS INC.**

BYLAWS OF SOLAR THERAPEUTICS INC.

ARTICLE I: GENERAL

Section 1.01 Name and Purposes. The name of the Corporation is Solar Therapeutics Inc. (the “Corporation”). The purpose of the Corporation shall be as set forth in the Corporation’s Articles of Entity Conversion as adopted and filed with the Office of the Secretary of State of the Commonwealth of Massachusetts (as now in effect or as hereafter amended or restated from time to time, the “Articles of Entity Conversion”) pursuant to Chapter 156D of the Massachusetts General Laws, as now in effect and as hereafter amended, or the corresponding provision(s) of any future Massachusetts General Law (“Chapter 156D”).

Section 1.02 Articles of Entity Conversion. These Bylaws (“Bylaws”), the powers of the Corporation and its shareholders and Board of Directors, and all matters concerning the conduct and regulation of the business of the Corporation, shall be subject to the provisions in regard thereto that may be set forth in the Articles of Entity Conversion. In the event of any conflict or inconsistency between the Articles of Entity Conversion and these Bylaws, the Articles of Entity Conversion shall control.

Section 1.03 Corporate Seal. The Board of Directors may adopt and alter the seal of the Corporation. The seal of the Corporation, if any, shall, subject to alteration by the Board of Directors, bear its name, the word “Massachusetts” and the year of its incorporation.

Section 1.04 Fiscal Year. The fiscal year of the Corporation shall commence on January 1, and end on the following December 31 of each year, unless otherwise determined by the Board of Directors.

Section 1.05 Location of Principal Office of the Corporation. The principal office of the Corporation shall be located at such place within the Commonwealth of Massachusetts as shall be fixed from time to time by the Board of Directors, and if no place is fixed by the Board of Directors, such place as shall be fixed by the President.

ARTICLE II: SHAREHOLDERS

Section 2.01 Place of Meeting. Meetings of the shareholders shall be held at any place within or without the Commonwealth of Massachusetts that may be designated by the Board of Directors. Absent such designation, meetings shall be held at the principal office. The Board of Directors may, in its discretion, determine that the meeting may be held solely by means of remote electronic communication. If authorized by the Board of Directors, and subject to any guidelines and procedures adopted by the Board of Directors, shareholders not physically present at a meeting of shareholders, may participate in a meeting of shareholders by means of electronic transmission by and to the Corporation or electronic video screen communication; and, may be considered present in person and may vote at a meeting of shareholders, whether held at a designated place or held solely by means of electronic transmission by and to the Corporation or electronic video screen communication, subject to the conditions imposed by applicable law.

Section 2.02 Annual Meeting. The annual meeting of shareholders of this Corporation shall be held on such date and at such time as may be designated from time to time by the Board

of Directors. At the annual meeting, Directors shall be elected, and any other business may be transacted that is within the power of the shareholders and allowed by law; *provided, however*, that unless the notice of meeting, or the waiver of notice of such meeting, sets forth the general nature of any proposal to (i) approve or ratify a contract or transaction with a Director or with a corporation, firm or association in which a Director has an interest; (ii) amend the Articles of Entity Conversion of this Corporation; (iii) approve a reorganization or merger involving this Corporation; (iv) elect to wind up and dissolve this Corporation; or (v) effect a plan of distribution upon liquidation otherwise than in accordance with the liquidation preferences of outstanding shares with liquidation preferences, no such proposal may be approved at an annual meeting.

Section 2.03 Special Shareholders' Meetings. Special meetings of the shareholders, for any purpose whatsoever, may be called at any time by the President, the Board of Directors or by shareholders entitled to cast not less than ten percent (10%) of the corporation's voting power. Any person entitled to call a special meeting of shareholders (other than the Board of Directors) may make a written request to the Chair of the Board (if any), President or Secretary, specifying the general purpose of such meeting and the date, time and place of the meeting, which date shall be not less than thirty-five (35) days nor more than sixty (60) days after the receipt by such officer of the request. Within twenty (20) days after receipt of the request, the officer receiving such request forthwith shall cause notice to be given to the shareholders entitled to vote at such meeting, stating that a meeting will be held on the date and at the time and place requested by the person or persons requesting a meeting and stating the general purpose of the meeting. If such notice is not given twenty (20) days after receipt by the officer of the request, the person or persons requesting the meeting may give such notice. No business shall be transacted at a special meeting unless its general nature shall have been specified in the notice of such meeting; *provided, however*, that any business may be validly transacted if the requirements for such validity, as provided in Section 2.12 of these Bylaws, are met.

Section 2.04 Shareholder Nominations and Proposals. For business (including, but not limited to Director nominations) to be properly brought before an annual or special meeting by a shareholder, the shareholder or shareholders of record intending to propose the business (the "Proposing Shareholder") must have given written notice of the Proposing Shareholder's nomination or proposal, either by personal delivery or by the United States mail to the Secretary of the Corporation. In the case of an annual meeting, the Proposing Shareholder must give such notice to the Secretary of the Corporation no earlier than one hundred and twenty (120) calendar days and no later than ninety (90) calendar days before the date such annual meeting is to be held. If the current year's meeting is called for a date that is not within thirty (30) days of the anniversary of the previous year's annual meeting, notice must be received not later than ten (10) calendar days following the day on which public announcement of the date of the annual meeting is first made. In no event will an adjournment or postponement of an annual meeting of shareholders begin a new time period for giving a Proposing Shareholder's notice as provided above.

For business to be properly brought before a special meeting of shareholders, the notice of meeting sent by or at the direction of the person calling the meeting must set forth the nature of the business to be considered. A shareholder or shareholders who have made a written request for a special meeting pursuant to Section 2.03 of these Bylaws may provide the information required for notice of a shareholder proposal under this Section 2.04 simultaneously with the written request for the

meeting submitted to the Secretary or within ten (10) calendar days after delivery of the written request for the meeting to the Secretary.

A Proposing Shareholder's notice shall include as to each matter the Proposing Shareholder proposes to bring before either an annual or special meeting:

- (a) The name(s) and address(es) of the Proposing Shareholder(s).
- (b) The classes and number of shares of capital stock of the Corporation held by the Proposing Shareholder.
- (c) If the notice regards the nomination of a candidate for election as Director:
 - (i) The name, age, business and residence address of the candidate;
 - (ii) The principal occupation or employment of the candidate; and
 - (iii) The class and number of shares of the Corporation beneficially owned by the candidate.
- (d) If the notice is in regard to a proposal other than a nomination of a candidate for election as Director, a brief description of the business desired to be brought before the meeting and the material interest of the Proposing Shareholder of such proposal.

Section 2.05 Notice of Shareholders' Meeting. Except as otherwise provided by law, written notice stating the place, day and hour of the meeting, and, in case of a special meeting, the nature of the business to be transacted at the meeting, shall be given at least ten (10) days (or, if sent by third class mail, thirty (30) days) and not more than sixty (60) days before the meeting. In the case of an annual meeting, notice will include matters the Corporation's Board of Directors intends, at the time of the giving of the first of such notices, to present to the shareholders for action, and in the case of a meeting at which Directors are to be elected, the names of nominees that the Board of Directors, at the time of the giving of the first of such notices, intends to present to the shareholders for election. Proof that notice was given shall be made by affidavit of the Secretary, assistant Secretary, transfer agent or Director, or of the person acting under the direction of any of the foregoing, who gives such notice, and such proof of notice shall be made part of the minutes of the meeting. Such affidavit shall be prima facie evidence of the giving of such notice. It shall not be necessary to state in a notice of any meeting of shareholders as a purpose thereof any matter relating to the procedural aspects of the conduct of such meeting.

Notice shall be given personally, by electronic transmission or by mail, by or at the direction of the Secretary, or the officer or person calling the meeting, to each shareholder entitled to vote at the meeting. If remote participation in the meeting has been authorized by the Board of Directors, the notice shall also provide a description of the means of any electronic transmission by and to the Corporation or electronic video screen communication by which shareholders may be considered present and may vote and otherwise participate at the meeting.

If mailed, the notice shall be deemed to be given when deposited in the United States mail addressed to the shareholder at the shareholder's address as it appears on the share transfer records

of the Corporation, with postage thereon prepaid. Notice may be given to the shareholder by electronic transmission with the consent of the shareholder. Notice by electronic transmission is deemed given when the notice satisfies any of the following requirements:

- (a) Transmitted to a facsimile number provided by the shareholder for the purpose of receiving notice.
- (b) Transmitted to an electronic mail address provided by the shareholder for the purpose of receiving notice.
- (c) Posted on an electronic network, with a separate notice sent to the shareholder at the address provided by the shareholder for the purpose of alerting the shareholder of a posting.
- (d) Communicated to the shareholder by any other form of electronic transmission consented to by the shareholder.

Notice shall not be given by electronic transmission to a shareholder after either (i) the Corporation is unable to deliver two consecutive notices to such shareholder by such means or (ii) the inability to deliver such notices to such shareholder becomes known to any person responsible for giving such notices. Any person entitled to notice of a meeting may file a written waiver of notice with the Secretary either before or after the time of the meeting. The participation or attendance at a meeting of a person entitled to notice constitutes waiver of notice, except where the person objects, at the beginning of the meeting, to the lawfulness of the convening of the meeting and except that attendance is not a waiver of any right to object to conducting business at a meeting that is required to be included in the notice of the meeting, but not so included.

Section 2.06 Persons Entitled to Vote. Except as otherwise provided by law, and except when a record date has been fixed, only persons in whose names shares entitled to vote stand on the stock records of the Corporation at the close of business on the business day next preceding the day on which notice is given shall be entitled to notice of a shareholders' meeting, or to vote at such meeting. In the event notice is waived, only persons in whose names shares entitled to vote stand on the stock records of the Corporation at the close of business on the business day next preceding the day on which the meeting is held shall be entitled to vote. If no record date has been fixed, the record date shall be:

- (a) For determining shareholders entitled to give consent to action by the Corporation without a meeting, the day on which the first written consent is given.
- (b) For determining shareholders for any other purpose, the later of (i) the day on which the Board of Directors adopts the resolution relating thereto, or (ii) the sixtieth (60th) day prior to the date of such other action.

Section 2.07 Fixing the Record Date. The Board of Directors may fix a time in the future as a record date to determine the shareholders entitled to notice of, and to vote at, any meeting of shareholders or give written consent to action by the Corporation without a meeting or entitled to receive any dividend or distribution, or to any change conversion, or exchange of shares.

A record date fixed under this Section 2.07 may not be more than sixty (60) days or less than ten (10) days before the meeting or more than sixty (60) days before any other action requiring a determination of shareholders. When a record date is so fixed, only shareholders of record at the close of business on that date are entitled to notice of and to vote at the meeting or to receive the dividend, distribution or allotment of rights, or to exercise the rights, as the case may be, notwithstanding any transfer of any shares on the books of the Corporation after the record date. In the event any meeting of shareholders is adjourned for more than forty-five (45) days from the date set for the original meeting, the Board shall fix a new record date for purposes of giving notice of, and determining the holders of shares entitled to vote at, such adjourned meeting.

Section 2.08 Quorum of and Action by Shareholders. The presence at a meeting in person or by proxy of the persons entitled to vote a majority of the voting shares constitutes a quorum for the transaction of business. The shareholders present at a duly called or held meeting at which a quorum is present may continue to do business until adjournment notwithstanding the withdrawal of such number of shareholders so as to leave less than a quorum, if any action taken, other than adjournment, is approved by at least a majority of the shares required to constitute a quorum, except as otherwise provided by law. Except as otherwise provided by law, herein or in the Articles of Entity Conversion, the affirmative vote of a majority of the shares represented at a meeting at which a quorum is present, shall be the act of the shareholders.

Section 2.09 Adjourned Meetings and Notice Thereof. Any shareholders' meeting, annual or special, whether or not a quorum is present, may be adjourned from time to time by a vote of the majority of the shares present, in person or proxy. When a meeting is adjourned for forty-five (45) days or more, or if a new record date for the adjourned meeting is fixed by the Board of Directors, notice of the adjourned meeting shall be given to such shareholders of record entitled to vote at the adjourned meeting, as in the case of any original meeting. When a meeting is adjourned for less than forty-five (45) days, and a new record date is not fixed by the Board of Directors, it shall not be necessary to give any notice of the time and place of the adjourned meeting, means of electronic transmission or electronic video screen communication, if any, or of the business to be transacted thereat other than by announcement at the meeting at which the adjournment is taken, provided only business that might have been transacted at the original meeting may be conducted at such adjourned meeting.

Section 2.10 Conduct of Meetings. The Board of Directors may adopt by resolution rules and regulations for the conduct of meetings of the shareholders as it shall deem appropriate. At every meeting of the shareholders, the President, or in his or her absence or inability to act, a Director or officer designated by the Board of Directors, shall serve as the presiding officer. The Secretary or, in his or her absence or inability to act, the person whom the presiding officer of the meeting shall appoint secretary of the meeting, shall act as secretary of the meeting and keep the minutes thereof.

The presiding officer shall determine the order of business and, in the absence of a rule adopted by the Board of Directors, shall establish rules for the conduct of the meeting. The presiding officer shall announce the close of the polls for each matter voted upon at the meeting, after which no ballots, proxies, votes, changes or revocations will be accepted. Polls for all matters before the meeting will be deemed to be closed upon final adjournment of the meeting.

Section 2.11 Voting of Shares. Unless otherwise provided by law or in the Articles of Entity Conversion, each shareholder entitled to vote is entitled to one (1) vote for each share of Common Stock. Any holder of shares entitled to vote on any matter may vote part of such shares in favor of the proposal and refrain from voting the remaining shares or vote them against the proposal. If a shareholder fails to specify the number of shares such shareholder is voting affirmatively, it will be conclusively presumed that the shareholder's approving vote is with respect to all shares such shareholder is entitled to vote.

Section 2.12 Consent of Absentees. The transactions of any meeting of shareholders, however called or noticed, are as valid as though had at a meeting duly held after regular call and notice, if a quorum is present either in person or by proxy, and if, either before or after the meeting, each of the persons entitled to vote, not present in person or by proxy, signs a written waiver of notice, or a consent to the holding of such meeting, or an approval of the minutes thereof. The waiver, notice or consent need not specify the business transacted or purpose of the meeting, except as required by Chapter 156D. All such waivers, consents or approvals shall be filed with the corporate records or made a part of the minutes of the meeting.

Section 2.13 Voting by Proxy or Nominee. Every person entitled to vote or execute consents may do so either in person or by one (1) or more agents authorized by a written proxy executed by the person or such person's duly authorized agent and filed with the Secretary of the Corporation. A proxy is not valid after the expiration of eleven (11) months from the date of its execution, unless the person executing it specifies therein the length of time for which it is to continue in force. Except as set forth below, any proxy duly executed is not revoked, and continues in full force and effect, until an instrument revoking it, or a duly executed proxy bearing a later date, executed by the person executing the prior proxy and presented to the meeting, is filed with the Secretary of the Corporation, or unless the person giving the proxy attends the meeting and votes in person, or unless written notice of the death or incapacity of the person executing the proxy is received by the Corporation before the vote by such proxy is counted. A proxy that states on its face that it is irrevocable will be irrevocable for the period of time specified in the proxy, if held by a person (or nominee of a person) specified by law to have sufficient interest to make such proxy irrevocable and only so long as he shall have such interest, subject to G.L. c. 156D, § 7.22.

Section 2.14 Action by Shareholders Without a Meeting. Any action, that, under any provision of Chapter 156D may be taken at a meeting of the shareholders, may be taken without a meeting and without prior notice if a consent in writing, setting forth the action so taken, shall be signed by the holders of the outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares are entitled to vote thereon were present and voted; *provided, however*, that unless the consents of all shareholders entitled to vote have been solicited in writing, notice shall be given (in the same manner as notice of meetings is to be given), and within the time limits prescribed by law, of such action to all shareholders entitled to vote who did not consent in writing to such action; and *provided, further*, that Directors may be elected by written consent only if such consent is unanimously given by all shareholders entitled to vote, except that action taken by shareholders to fill one (1) or more vacancies on the Board other than a vacancy created by the removal of a Director, may be taken by written consent of a majority of the outstanding shares entitled to vote.

ARTICLE III: DIRECTORS

Section 3.01 Number of Directors; Identity of Initial Directors. The authorized number of Directors of the Corporation shall be three (3) until changed by an amendment to these Bylaws duly adopted in accordance with these Bylaws by the vote or written consent of a majority of the outstanding shares entitled to vote. The initial Directors shall be:

- (a) Edward Dow III.;
- (b) Ronald Rapoport; and
- (c) Michael Maxim;

Section 3.02 Powers. All corporate power shall be exercised by, or under the authority of, and the business and affairs of the Corporation shall be managed under the direction of, the Board of Directors, except such powers expressly conferred upon or reserved to the shareholders, and subject to any limitations set forth by law, by the Articles of Entity Conversion or by these Bylaws.

Without limiting the generality of the foregoing, and subject to the same limitations, it is hereby expressly declared that the Directors shall have the power and, to the extent required by law, the duty to:

(a) Appoint and remove at pleasure of the Board all officers, managers, management companies, agents and employees of the Corporation, prescribe their duties in addition to those prescribed in these Bylaws, supervise them, fix their compensation and require from them security for faithful service. Such compensation may be increased or diminished at the pleasure of the Directors;

(b) Conduct, manage and control the affairs and business of the Corporation, make rules and regulations not inconsistent with the Articles of Entity Conversion or applicable law or these Bylaws, make all lawful orders on behalf of the Corporation and prescribe in the manner of executing the same;

(c) Incur indebtedness and borrow money on behalf of the Corporation and designate from time to time the person or persons who may sign or endorse checks, drafts or other orders of payment of money, notes or other evidences of indebtedness, issued in the name of, or payable to, the Corporation, and prescribe the manner of collecting or depositing funds of the Corporation and the manner of drawing checks thereon;

(d) Appoint by resolution of a majority of the authorized number of Directors an executive committee and other committees and delegate to the executive committee any of the powers and authorities of the Board in the management of the business and affairs of the Corporation, except the powers to (i) fill vacancies on the Board or any committee, (ii) fix compensation of Directors; (iii) adopt, amend or repeal these Bylaws; (iv) amend or repeal resolutions of the Board that are expressly non-amendable or not able to be repealed; (v) declare a dividend or distribution to shareholders or authorize the repurchase of the Corporation's shares except at a rate, in a periodic amount or within a range,

determined by the Board; (vi) establish other committees of the Board; or (vii) approve any action that in addition to Board approval requires shareholder approval. The executive committee shall be composed of two (2) or more Directors. The provisions of these Bylaws regarding notice and meetings of Directors shall apply to all committees;

(e) Authorize the issuance of stock of the Corporation from time to time, upon such terms as may be lawful; and

(f) Prepare an annual report to be sent to the shareholders after the close of the fiscal or calendar year of this Corporation, which report shall comply with the requirements of law. To the extent permitted by law, the requirements that an annual report be sent to shareholders and the time limits for sending such reports are hereby waived, the Directors, nevertheless, having the authority to cause such report to be sent to shareholders.

Section 3.03 Term of Office. Directors shall hold office until the next annual meeting of shareholders and until their successors are elected.

Section 3.04 Vacancies and Newly Created Directorships. A vacancy on the Board of Directors exists in case of the occurrence of any of the following events:

(a) The death, resignation or removal of any Director.

(b) The removal or declaration of vacancy by the Board of Directors of a Director who has been declared of unsound mind by a court order or convicted of a felony.

(c) The Director is a member who is divested from ownership of the marijuana business resulting from a decision by either the state or local licensing authority.

(d) The authorized number of Directors is increased.

(e) At any annual, regular or special meeting of shareholders at which any Director is elected, the shareholders fail to elect the full authorized number of Directors to be voted for at that meeting.

All vacancies may be filled by the approval of the Board of Directors or, if there is less than a quorum of Directors, by (i) a vote of the majority of the remaining Directors at a meeting held pursuant to notice or waivers of notice complying with G.L. c. 156D, (ii) unanimous written consent or (iii) a sole remaining Director. Each Director so elected shall hold office until his successor is elected at an annual, regular or special meeting of the shareholders. The shareholders may, by vote or written consent of a majority of outstanding shares entitled to vote in the election of Directors, elect a Director at any time to fill any vacancy not filled by the Directors. The shareholders may, by vote of a majority of outstanding shares entitled to vote in the election of Directors or unanimous written consent, elect a Director at any time to fill any vacancy created by removal of a Director, except that a vacancy created pursuant to clause (b) of this Section 3.04 may be filled by the Board of Directors. If the Board of Directors accepts the resignation of a Director tendered to take effect at a future time, the Board or the shareholders may elect a successor to take office when the resignation becomes effective. A reduction of the authorized number of Directors does not remove any Director prior to the expiration of that Director's term of office.

Section 3.05 Removal. The Board of Directors may declare vacant the office of a Director who has been declared of unsound mind by an order of the court or convicted of a felony, or who has been barred from ownership of a marijuana business by a final decision of an applicable state or local licensing authority, or otherwise in a manner provided by law.

Any or all of the Directors may be removed from office at any duly called meeting without cause by a vote of the shareholders entitled to elect them. If one (1) or more Directors are so removed at a meeting of shareholders, the shareholders may elect new Directors at the same meeting.

Section 3.06 Resignation. A Director may resign effective on giving written notice to the President, unless the notice specifies a later effective date.

Section 3.07 Meetings of Directors.

(a) **Regular Meetings.** A regular annual meeting of the Board shall be held immediately after, and at the same place as, the annual meeting of shareholders for the purpose of electing officers and transacting any other business. The Board may provide for other regular meetings from time to time by resolution.

(b) **Special Meetings.** Special meetings of the Board for any purpose or purposes may be called at any time by the President, the Secretary, by any two (2) Directors or by one (1) Director in the event that there is only one (1) Director. Notice of the time and place of special meetings shall be delivered by mail, electronic delivery or orally. If notice is mailed, it shall be deposited in the United States mail at least four (4) days before the time of the meeting. In the case the notice is delivered either orally or by electronic delivery shall be delivered at least forty-eight (48) hours before the time of the meeting. Any oral notice given personally or by telephone may be communicated either to the Director or to a person at the office of the Director whom the person giving notice has reason to believe will promptly communicate it to the Director. The notice need not specify the purpose of the meeting nor the place if it is to be held at the principal office of the Corporation.

(c) **Place of Meetings.** Meetings of the Board may be held at any place within or without the Commonwealth of Massachusetts that has been designated in the notice. If a place has not been stated in the notice or there is no notice, meetings shall be held at the principal office of the Corporation unless another place has been designated by a resolution duly adopted by the Board.

Section 3.08 Electronic Participation. Members of the Board may participate in a meeting through conference telephone, electronic video screen communication or other electronic transmission by and to the Corporation. Participation in a meeting by conference telephone or electronic video screen communication constitutes presence in person as long as all Directors participating can hear one another. Participation by other electronic transmission by and to the Corporation (other than conference telephone or electronic video screen communication) constitutes presence in person at the meeting as long as participating Directors can communicate with other participants concurrently, each Director has the means to participate in all matters before the Board, including the ability to propose or object to a specific corporate action, and the

Corporation implements some means of verifying that each person participating is entitled to participate and all votes or other actions are taken by persons entitled to participate.

Section 3.09 Quorum of and Action by Directors. A majority of the authorized number of Directors constitutes a quorum of the Board for the transaction of business. Every act or decision done or made by a majority of the Directors present at a meeting duly held at which a quorum is present is the act of the Board of Directors, unless G.L. c. 156D or the Articles of Entity Conversion require a greater number. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of Directors, if any action is approved by at least a majority of the Directors who constitute the required quorum for such meeting. A quorum of the Directors may adjourn any Directors' meeting to meet again at a stated time and place. In the absence of quorum, a majority of the Directors present may adjourn from time to time. Notice of the time and place of a meeting that has been adjourned for more than twenty-four (24) hours shall be given to the Directors not present at the time of the adjournment.

Section 3.10 Compensation. Directors may receive compensation for their services, and the Board of Directors may authorize payment of a fixed fee and expenses of attendance, if any, for attendance at any meeting of the Board of Directors or committee thereof. A Director shall not be precluded from serving the Corporation in any other capacity and receiving compensation for services in that capacity. The Directors may, from time to time, establish compensation policies of the Corporation consistent with this Section 3.10.

Section 3.11 Action by Directors Without a Meeting. Any action required or permitted to be taken by the Board of Directors or any committee thereof under G.L. c. 156D may be taken without a meeting if, prior or subsequent to the action, a consent or consents thereto by all of the Directors in office, or all the committee members then appointed, is filed with the Secretary to be filed with the minutes of the proceedings of the Board of Directors. Such action by written consent shall have the same force and effect as a unanimous vote of such Directors.

Section 3.12 Committees of the Board of Directors. The Board of Directors, by resolution adopted by a majority of authorized Directors, may designate one (1) or more committees, each consisting of two (2) or more Directors, to serve at the pleasure of the Board and to exercise the authority of the Board of Directors to the extent provided in the resolution establishing the committee and permitted by law. The Board of Directors may adopt governance rules for any committee consistent with these Bylaws. The provisions of these Bylaws applicable to meetings and actions of the Board of Directors shall govern meetings and actions of each committee, with the necessary changes made to substitute the committee and its members for the Board of Directors and its members.

A committee of the Board of Directors does not have the authority to:

- (a) Approve actions that require approval of the shareholders or the outstanding shares.
- (b) Fill vacancies on the Board or in any committee.
- (c) Fix compensation of the Directors for serving on the Board or on any committee.

- (d) Amend or repeal bylaws or adopt new bylaws.
- (e) Amend or repeal any resolution of the Board of Directors that by its terms is not so amendable or repealable.
- (f) Make a distribution to shareholders, except at a rate, in a periodic amount or within a price range set forth in the Articles of Entity Conversion or determined by the Board.
- (g) Appoint other committees or Board members.

The Board of Directors, by resolution adopted by the majority of authorized Directors, may designate one (1) or more Directors as alternate members of any committee who may replace any absent or disqualified member at any meeting of the committee or for the purposes of any written action by the committee.

The designation of a committee of the Board of Directors and the delegation thereto of authority shall not operate to relieve the Board of Directors, or any member thereof, of any responsibility imposed by law.

ARTICLE IV: OFFICERS

Section 4.01 Positions and Election. The officers of the Corporation shall be elected by the Board of Directors and shall be a President, a Secretary, a Treasurer and all other officers as may from time to time be determined by the Board of Directors. At the discretion of the Board of Directors, the Corporation may also have other officers, including but not limited to one (1) or more Vice Presidents or assistant Vice Presidents, one (1) or more assistant Secretaries, a Chief Financial Officer and a Chief Operations Officer, as may be appointed by the Board of Directors, with such authority as may be specifically delegated to such officers by the Board of Directors. Any two (2) or more offices may be held by the same person.

Officers shall be elected annually at the meeting of the Board of Directors held after each annual meeting of shareholders. Each officer shall serve until a successor is elected and qualified or until the earlier death, resignation or removal of that officer. Vacancies or new offices shall be filled at the next regular or special meeting of the Board of Directors.

Section 4.02 Removal and Resignation. Any officer elected or appointed by the Board of Directors may be removed with or without cause by the affirmative vote of the majority of the Board of Directors. Removal shall be without prejudice to the contract rights, if any, of the officer so removed.

Any officer chosen by the Board of Directors may resign at any time by giving written notice to the Corporation. Unless a different time is specified in the notice, the resignation shall be effective upon its receipt by the President, the Secretary or the Board.

Section 4.03 Powers and Duties of Officers. The powers and duties of the officers of the Corporation shall be as provided from time to time by resolution of the Board of Directors or by direction of an officer authorized by the Board of Directors to prescribe the duties of other

officers. In the absence of such resolution, the respective officers shall have the powers and shall discharge the duties customarily and usually held and performed by like officers of corporations similar in organization and business purposes to the Corporation subject to the control of the Board of Directors.

ARTICLE V: INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 5.01 Indemnification of Officers or Directors. The Corporation shall, to the extent permitted by G.L. c. 156D, indemnify all persons who have served or may serve at any time as officers or Directors of the Corporation and their heirs, executors, administrators, successors and assigns, from and against any and all loss and expense, including amounts paid in settlement before or after suit is commenced, and reasonable attorney's fees, actually and necessarily incurred as a result of any claim, demand, action, proceeding or judgment that may have been asserted against any such persons, or in which these persons are made parties by reason of their being or having been officers or Directors of the Corporation. This right of indemnification shall not exist in relation to matters as to which it is adjudged in any action, suit or proceeding that these persons are liable for negligence or misconduct in the performance of duty.

Section 5.02 Non-Exclusivity of Indemnification Rights and Authority to Insure. The foregoing rights of indemnification and advancement of expenses shall be in addition to and not exclusive of any other rights to which any person may be entitled pursuant to any agreement with the Corporation, or under any statute, provision of the Articles of Entity Conversion or any action taken by the Directors or shareholders of the Corporation.

The Corporation may buy and maintain insurance to protect itself and any agent against any expense asserted against them or incurred by an agent, whether or not the Corporation could indemnify the agent against the expense under applicable law or the provisions of this Article V.

ARTICLE VI: SHARE CERTIFICATES AND TRANSFER

Section 6.01 Share Certificates. Shares of the Corporation may, but need not, be represented by certificates. Each certificate issued shall bear all statements or legends required by law to be affixed thereto. For all shares issued or transferred without certificates, the Corporation shall within a reasonable time after such issuance or transfer send the shareholder a written statement of the information required on share certificates pursuant to G.L. c. 156D, § 6.25(b) & (c) and § 6.27. Shareholders can request and obtain a statement of rights, restrictions, preferences and privileges regarding classified shares or a class of shares with two (2) or more series, if any, from the Corporation's principal office. Each certificate issued shall bear all statements or legends required by law to be affixed thereto.

Every certificate for shares shall be signed by (i), the President, or a Vice President and (ii) the Chief Financial Officer, an assistant Treasurer, the Secretary or any assistant Secretary.

Section 6.02 Transfers of Shares. Transfer of shares of the Corporation shall be made only on the books of the Corporation by the registered holder thereof or by such other person as may under law be authorized to endorse such shares for transfer, or by such shareholder's attorney thereunto authorized by power of attorney duly executed and filed with the Secretary or transfer agent of the Corporation. Except as otherwise provided by law, upon surrender to the Corporation

or its transfer agent of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books.

Section 6.03 Registered Shareholders. The Corporation may treat the holder of record of any shares issued by the Corporation as the holder in fact thereof, for purposes of voting those shares, receiving distributions thereon or notices in respect thereof, transferring those shares, exercising rights of dissent with respect to those shares, exercising or waiving any preemptive right with respect to those shares, entering into agreements with respect to those shares in accordance with the laws of the Commonwealth of Massachusetts or giving proxies with respect to those shares.

Section 6.04 Lost, Stolen, or Destroyed Certificates. The Board of Directors may issue a new share certificate in place of any certificate it previously issued that the shareholder alleges to have been lost, stolen or destroyed provided that the shareholder or the shareholder's legal representative of the lost, stolen or destroyed certificate shall give the Corporation a bond or other adequate security sufficient to indemnify the Corporation against any potential claim against the Corporation because of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

ARTICLE VII: CORPORATE RECORDS AND INSPECTION

Section 7.01 Records. The Corporation shall maintain adequate and correct books and records of account, minutes of the proceedings of the shareholders, Board of Directors and committees of the Board of Directors, and a record of its shareholders, including names and addresses of all shareholders and the number and class of shares held, along with any other records required by law. The Corporation shall keep such record of its shareholders at its principal office, as fixed by the Board of Directors from time to time, or at the office of its transfer agent or registrar. The Corporation shall keep its books and records of account and minutes of the proceedings of the shareholders, Board of Directors and committees of the Board of Directors at its principal office, or such other location as shall be designated by the Board of Directors from time to time.

Section 7.02 Inspection of Books and Records. The Corporation's accounting books and records and minutes of proceedings of the shareholders, Board of Directors and committees of the Board of Directors shall, to the extent provided by law, be open to inspection of Directors, shareholders and voting trust certificate holders, in the manner provided by law.

Section 7.03 Certification and Inspection of Bylaws. The Corporation shall keep in its principal office the original or a copy of these Bylaws as amended or otherwise altered to date, which shall be open to inspection by the shareholders at all reasonable times during office hours.

ARTICLE VIII: MISCELLANEOUS

Section 8.01 Checks, Drafts, Etc. All checks, drafts or other instruments for payment of money or notes of the Corporation shall be signed by an officer or officers or any other person or persons as shall be determined from time to time by resolution of the Board of Directors.

Section 8.02 Conflict with Applicable Law or Articles of Entity Conversion. Unless the context requires otherwise, the general provisions, rules of construction and the definitions of G.L. c. 156D shall govern the construction of these Bylaws. These Bylaws are adopted subject to any applicable law and the Articles of Entity Conversion. Whenever these Bylaws may conflict with any applicable law or the Articles of Entity Conversion, such conflict shall be resolved in favor of such law or the Articles of Entity Conversion.

Section 8.03 Invalid Provisions. If any one (1) or more of the provisions of these Bylaws, or the applicability of any provision to a specific situation, shall be held invalid or unenforceable, the provision shall be modified to the minimum extent necessary to make it or its application valid and enforceable, and the validity and enforceability of all other provisions of these Bylaws and all other applications of any provision shall not be affected thereby.

Section 8.04 Emergency Management of the Corporation. In anticipation of or during an emergency, as defined in G.L. c. 156D, § 3.03(d), the Board, in order to conduct the ordinary business affairs of the Corporation, shall modify procedures, including, but not limited to, calling a board meeting, quorum requirements for such board meeting and designation of additional or substitute Directors; *provided*, that such modifications may not conflict with the Articles of Entity Conversion.

In anticipation of or during an emergency, the Corporation shall be able to take any and all of the following actions to conduct the Corporation's ordinary business affairs and operations:

- (a) Modify lines of succession to accommodate the incapacity of any Director, officer, employee or agent resulting from the emergency.
- (b) Relocate the principal office or designate alternative principal offices or regional offices.
- (c) Give notice to Directors in any practicable matter under the circumstances, including but not limited to publication and radio, when notice of a board meeting cannot be given in a manner prescribed by these Bylaws.
- (d) Deem that one (1) or more officers present at a board meeting is a Director as necessary to achieve a quorum for that meeting.

Section 8.05 Reports. The Corporation shall provide all shareholders with notice of the availability of annual financial reports of the Corporation before the earlier of the annual meeting of the shareholders or one hundred and twenty (120) days after the close of the fiscal year. Such financial reports shall be prepared and provided to the shareholders upon request in compliance with G.L. c. 156D, § 16.20.

Section 8.06 Advisement of Counsel. THE CULTIVATION, PRODUCTION AND SALE OF CANNABIS IS ILLEGAL UNDER FEDERAL LAW. NEITHER PARTY, NOR ATTORNEYS FOR COMPANY, HAVE MADE ANY REPRESENTATION TO THE CONTRARY.

ARTICLE IX: AMENDMENT OF BYLAWS

Section 9.01 Amendment by Shareholders. Shareholders may adopt, amend or repeal these Bylaws by the vote or written consent of the holders of a majority of the outstanding shares entitled to vote, except as otherwise provided by law, these Bylaws or the Articles of Entity Conversion.

Section 9.02 Amendment by Directors. Subject to the rights of shareholders as provided in Section 9.01, and the statutory limitations of G.L. c. 156D, the Board of Directors may adopt, amend or repeal these Bylaws.

[SIGNATURE PAGE TO FOLLOW]


**CERTIFICATE OF SECRETARY
OF
Solar Therapeutics Inc.**

The undersigned, Michael Maxim, hereby certifies that [s]he is the duly elected and acting Secretary of SOLAR THERAPEUTICS INC., a Massachusetts corporation (the "Corporation"), and that the foregoing Bylaws were adopted as the Bylaws of the Corporation as of _____, 2018, and that the same do now constitute the Bylaws of the Corporation.

IN WITNESS WHEREOF, the undersigned has executed this certificate on behalf of the Corporation as of this 16 day of JULY, 2018.

SOLAR THERAPEUTICS INC.

By: Michael Maxim
Name: Michael Maxim
Title: Secretary



The Commonwealth of Massachusetts
Secretary of the Commonwealth
State House, Boston, Massachusetts 02133

William Francis Galvin
Secretary of the
Commonwealth

Date: December 30, 2019

To Whom It May Concern :

I hereby certify that according to the records of this office,
SOLAR THERAPEUTICS INC.

is a domestic corporation organized on **August 02, 2018** , under the General Laws of the Commonwealth of Massachusetts. I further certify that there are no proceedings presently pending under the Massachusetts General Laws Chapter 156D section 14.21 for said corporation's dissolution; that articles of dissolution have not been filed by said corporation; that, said corporation has filed all annual reports, and paid all fees with respect to such reports, and so far as appears of record said corporation has legal existence and is in good standing with this office.



In testimony of which,
I have hereunto affixed the
Great Seal of the Commonwealth
on the date first above written.

William Francis Galvin

Secretary of the Commonwealth

Certificate Number: 19120652170

Verify this Certificate at: <http://corp.sec.state.ma.us/CorpWeb/Certificates/Verify.aspx>

Processed by:



CERTIFICATE OF GOOD STANDING AND/OR TAX COMPLIANCE



ROBERT KELLER
SOLAR THERAPEUTICS, INC.
1400 BRAYTON POINT RD
SOMERSET MA 02725-2301

Why did I receive this notice?

The Commissioner of Revenue certifies that, as of the date of this certificate, SOLAR THERAPEUTICS, INC. is in compliance with its tax obligations under Chapter 62C of the Massachusetts General Laws.

This certificate doesn't certify that the taxpayer is compliant in taxes such as unemployment insurance administered by agencies other than the Department of Revenue, or taxes under any other provisions of law.

This is not a waiver of lien issued under Chapter 62C, section 52 of the Massachusetts General Laws.

What if I have questions?

If you have questions, call us at (617) 887-6400 or toll-free in Massachusetts at (800) 392-6089, Monday through Friday, 8:30 a.m. to 4:30 p.m..

Visit us online!

Visit mass.gov/dor to learn more about Massachusetts tax laws and DOR policies and procedures, including your Taxpayer Bill of Rights, and MassTaxConnect for easy access to your account:

- Review or update your account
- Contact us using e-message
- Sign up for e-billing to save paper
- Make payments or set up autopay

Edward W. Coyle, Jr., Chief
Collections Bureau



Solar Therapeutics, Inc.

BUSINESS PLAN

Town of Seekonk

May 2019

Business Plan Table of Contents

1. EXECUTIVE SUMMARY

2. COMPANY OVERVIEW

3. MARKET RESEARCH

4. PRODUCTS & SERVICES

5. SALES & MARKETING

6. FINANCIAL PROJECTIONS

7. TEAM

8. FINAL REMARKS

1. EXECUTIVE SUMMARY

Mission Statement and Message from the CEO

Solar Therapeutics Inc. (“Solar Thera”) is a local, community focused operator with a demonstrated track record of professional Marijuana Establishment operations. The Company is committed to creating an inclusive and positive community environment in Seekonk that provides consistent, high quality alternative therapy and wellness products to consumers who are 21 years of age or older. Solar Thera’s experienced management team, dedicated board, and passionate investors are driven by a singular mission: to provide industry-leading alternative therapies with a sustainable energy footprint.

Our Products

Solar Thera will offer a variety of cannabis products that will be compliant with the guidelines and regulations set out by the Commonwealth. In addition to traditional sativa, indica, and hybrid cannabis flower, Solar Thera will offer a range of products and services that will allow the company to serve customers. Products Solar Thera intends to offer include, but will not be limited to:

1. Cannabis Flower and Prerolls
2. Concentrates and Vape Cartridges
3. Tinctures, Edibles, Tablets and Beverages
4. Topical Salves, Creams, Lotions, Patches and Sprays

What Drives Us

1. Serving customers 21 years of age or older with a wide variety of high quality products that are safe, effective and consistent;
2. Assisting local communities, including in offsetting the cost of Solar Thera’s operations within their communities;
3. Hiring employees and contractors from within the communities served;
4. Hiring employees and contractors from communities that have been particularly harmed by the war on drugs;
5. Hiring employees from economically distressed communities and giving them the space and knowledge to flourish professionally within Solar Thera and the cannabis industry as a whole;
6. Having a diverse and socially representative pool of employees;
7. Empowering the next generation of entrepreneurs and leaders through hiring, training, and teaching; and

8. Running environmentally friendly cultivation and dispensary sites in the Commonwealth of Massachusetts;

2. COMPANY OVERVIEW

2.1 Introduction

Solar Thera's corporate headquarters are located in Somerset, Massachusetts where the company operates a leased microgrid, a solar-powered state of the art cultivation facility, and the company's first dispensary.

The facility encompasses a total of almost 70,000 square feet, with approximately 36,000 square feet dedicated exclusively to cultivation and approximately 30,000 square feet of space dedicated to supporting cultivation and dispensary efforts.

Solar Thera is organized as a Massachusetts domestic for-profit corporation and has secured a Certificate of Registration from the Massachusetts Cannabis Control Commission (the "**Commission**") to operate in the Commonwealth.

2.2 Operations

Solar Thera has established extensive Standard Operating Procedures for all facets of the company's operations including inventory controls and procedures for reviewing comprehensive inventories of marijuana products in the process of cultivation, manufacture, and distribution.

Solar Thera will tag and track all marijuana seeds, clones, plants, marijuana products, and sales using a seed-to-sale methodology in a form and manner approved by the Commission.

No marijuana products will be sold or otherwise marketed that is not tested by Independent Testing Laboratories, except as allowed under 935 CMR 500.000.

Solar Thera maintains records, which are available for inspection by the Commission upon request. The records are maintained in accordance with generally accepted accounting principles.

Solar Thera has obtained and maintains general liability insurance coverage for no less than \$1,000,000 per occurrence and \$2,000,000 in aggregate, annually, and product liability insurance coverage for no less than \$1,000,000 per occurrence and \$2,000,000 in aggregate, annually, except as provided in 935 CMR 500.105(10)(b) or otherwise approved by the Commission. The deductible for each policy will be no higher than \$5,000 per occurrence.

Solar Thera provides adequate lighting, ventilation, temperature, humidity, space, and equipment, in accordance with applicable provisions of 935 CMR 500.105 and 500.110.

All recyclables and waste, including organic waste composed of or containing finished marijuana and marijuana products, are stored, secured, and managed in accordance with applicable state and local statutes, ordinances, and regulations. Organic material, recyclable material, solid waste, and liquid waste containing marijuana or by-products of marijuana processing will be disposed of in compliance with all applicable state and federal requirements.

Prior to commencing operations, Solar Thera will provide proof of having obtained a surety bond in an amount equal to its licensure fee payable to the Marijuana Regulation Fund. The bond will ensure payment of the cost incurred for the destruction of cannabis goods necessitated by a violation of St. 2016, c. 334, as amended by St. 2017, c. 55 or 935 CMR 500.000 or the cessation of operation of Solar Thera.

Solar Thera and Solar Thera agents will comply with all local rules, regulations, ordinances, and bylaws.

2.3 Security

Solar Thera will contract with a professional security and alarm company to design, implement, and monitor a comprehensive security plan to ensure that the facility is a safe and secure environment for employees and the local community. Solar Thera's state-of-the-art security system will consist of perimeter windows, as well as duress, panic, and holdup alarms connected to local law enforcement for efficient notification and response in the event of a security threat. The system will also include a failure notification system that will immediately alert the executive management team if a system failure occurs.

A redundant alarm system will be installed to ensure that active alarms remain operational if the primary system is compromised.

Interior and exterior HD video surveillance of all areas that contain marijuana, entrances, exits, and parking lots will be operational 24/7 and available to the Seekonk Police Department. These surveillance cameras will remain operational even in the event of a power outage.

The exterior of the dispensary and surrounding area will be sufficiently lit, and foliage will be minimized to ensure clear visibility of the area at all times.

Only Solar Thera's registered agents and other authorized visitors (e.g. contractors,

vendors) will be allowed access to the facility, and a visitor log will be maintained in perpetuity.

All agents and visitors will be required to visibly display an ID badge, and Solar Thera will maintain a current list of individuals with access.

On-site consumption of marijuana by Solar Thera's employees and visitors will be prohibited.

Solar Thera will have security personnel on-site during business hours.

2.4 Benefits to Seekonk

Solar Thera looks forward to working cooperatively with the Town of Seekonk, which approved the 2016 Ballot Question 4 legalizing adult use marijuana. To ensure that Solar Thera operates as a responsible, contributing member of the Seekonk community. Solar Thera anticipates establishing a mutually beneficial relationship with the Town in exchange for permitting Solar Thera to site and operate in Seekonk. The Town stands to benefit in various ways, including but not limited to the following:

- **Jobs:**
 - A dispensary will add over 40 full-time and part time jobs, in addition to hiring qualified, local contractors and vendors.
- **Monetary Benefits:**
 - A Host Community Agreement with significant monetary contributions and donations will provide the Town with additional financial benefits beyond local property taxes.
- **Access to Quality Product:**
 - Solar Thera will allow qualified consumers in the Commonwealth to have access to high quality cannabis flower and products that are tested for cannabinoid content and contaminants.
- **Control:**
 - In addition to the Commission, the Seekonk Police Department and other municipal departments will have oversight over Solar Thera's security systems and processes.
- **Responsibility:**
 - Solar Thera is comprised of experienced Marijuana Establishment operators and professionals who have been thoroughly background checked and evaluated by

the Commission to meet and exceed the stringent criteria.

- **Economic Development:**

- Solar Thera's involvement and development in the community will contribute to the revitalization of the area and contribute to the overall economic development of the local community.

2.5 Zoning

To be located in a newly renovated approx. 1,650 sq. ft. building at 1735 Fall River Ave., the proposed retail establishment complies with all Seekonk zoning requirements and bylaws and includes sufficient on and off site parking accommodations.

Solar Therapeutics will remain compliant at all times with the local zoning requirements set forth in the Town of Seekonk Zoning By-Law. In accordance with Zoning By-Law Section 6.10.3.2, Solar Thera's proposed marijuana retailer facility is located in an AED & MOD designated zone for retailer marijuana establishments.

In compliance with 935 CMR 500.110(3), the property is not located within 500 feet of any public or private school providing education in kindergarten or any of grades 1 through 12.

Additionally, and in compliance with Seekonk Zoning By-Law Section 6.10.3.2, Solar Thera's proposed site is not located within 1,000 feet of the following: (i) School, including a public or private elementary, vocational, or secondary school or a public or private college, junior college, or university; (ii) Child Care Facility; (iii) Library; (iv) Playground; (v) Public Park; (vi) Youth center; (vii) Public swimming pool (viii) Video arcade facility; or (ix) Similar facility in which minors commonly congregate.

3. MARKET RESEARCH

3.1 Industry

The Cannabis Industry is among the fastest growing industries in the United States. Sales revenues continue to increase each year with conservative estimates of \$18-\$20 billion in annual sales of cannabis by 2020. Estimates for the Massachusetts legal cannabis market range from \$1.17B - \$1.2B in 2020 (Source: ArcView Market Research and New Frontier).

3.2 Customers

Solar Thera's target customers include adults 21 years of age and older seeking high quality alternative therapy and wellness products.

3.3 Competitors

Solar Thera's competitors include other local, regional, and national cannabis dispensary and cultivation operators.

3.4 Competitive Advantage

Solar Thera's competitive advantages include a diverse and experienced management and operations team, along with the company's state of the art sustainability and energy efficiency infrastructure. By owning our power generation and microgrid assets, which consist of a combination of solar arrays, battery storage, and cogeneration units, the company is able to achieve an offset of at least 60% of carbon emissions as compared to the industry standard grid power.

State of the art switchgear, 100% LED lights and automated control systems further reduce the company's energy demand while increasing energy efficiency and manufacturing productivity. Solar Thera's internal irrigation is a closed loop system allowing Solar Thera to recapture approximately 90% of the water used in the agricultural process, minimizing fresh water consumption and discarded waste.

Sustainable design principles continue through to the retail dispensing locations with the company reducing waste when possible by using recycled and paper packaging, LED lights, recycling programs and highly efficient heating and cooling technology.

All of these elements combined afford the company full control over the supply chain and production quality of its products for consumers, and eliminate dependency on turbulent third party supplier and wholesale relationships.

3.5 Regulations

Solar Thera is a Marijuana Establishment, consistent with the objectives of St. 2016, c. 334, as amended by St. 2017, c. 55 and 935 CMR 500.000.

Solar Thera is registered to do business in the Commonwealth as a domestic business corporation. Solar Thera will maintain the corporation in good standing with the Massachusetts Secretary of the Commonwealth and the Department of Revenue.

Solar Thera will apply for all state and local permits and approvals required to build and operate the facility.

Solar Thera will also work cooperatively with various municipal departments in Seekonk

to ensure that the proposed facility complies with all state and local codes, rules and regulations with respect to design, renovation, operation, and security.

4. PRODUCTS & SERVICES

Our core products will be cannabis flower and cannabis derivative products, which will come in a variety of strains and product types. We will also engage in the sale of marijuana related products, such as accessories and hardware.

4.2 Pricing Structure

Solar Thera's pricing structure will vary based on market conditions. The Company plans to produce products of superior quality and will price its products accordingly.

5. SALES & MARKETING

5.1 Growth Strategy

The Company will seek additional, appropriate locations in the surrounding area to expand business and reach an increasing number of customers in the future. Solar Thera's plan to grow the company includes:

1. Strong and consistent branding;
2. Intelligent, targeted, and compliant marketing programs;
3. A compelling loyalty program;
4. An exemplary customer in-store experience;
5. A caring and thoughtful staff of consummate professionals

5.2 Communication

Solar Thera will engage in reasonable marketing, advertising, and branding practices that do not jeopardize the public health, welfare, or safety of the general public, or promote the diversion of marijuana or marijuana use in individuals younger than 21 years old. Any such marketing, advertising, and branding created for viewing by the public will include the statement: "Please Consume Responsibly," in a conspicuous manner on the face of the advertisement and will include a minimum of two of the warnings, located at 935 CMR 500.105(4)(a), in their entirety in a conspicuous manner on the advertisement.

All marketing, advertising, and branding produced by or on behalf of Solar Thera will include the following warning, including capitalization, in accordance with M.G.L. c. 94G, § 4(a1/2)(xxvi): "This product has not been analyzed or approved by the Food and Drug Administration (FDA). There is limited information on the side effects of using this product, and there may be associated health risks. Marijuana use during pregnancy and breast-feeding may

pose potential harms. It is against the law to drive or operate machinery when under the influence of this product. KEEP THIS PRODUCT AWAY FROM CHILDREN. There may be health risks associated with consumption of this product. Marijuana can impair concentration, coordination, and judgment. The impairment effects of edible marijuana may be delayed by two hours or more. In case of accidental ingestion, contact poison control hotline 1-800-222-1222 or 9-1-1. This product may be illegal outside of MA.”

Solar Thera will communicate with customers through:

1. A company run website;
2. A company blog;
3. Popular cannabis discover networks such as WeedMaps and Leafly;
4. Popular social media platforms such as Instagram, Facebook, Twitter, and SnapChat;
5. Opt-in direct communications;

Solar Thera will provide a catalogue and a printed list of the prices and strains of marijuana available to consumers and will post the same catalogue and list on its website and in the retail store.

5.3 Sales

Solar Thera will sell its product and service by engaging customers with knowledgeable in-store personnel.

Solar Thera will seek events where 85% or more of the audience is reasonably expected to be 21 years of age or older, as determined by reliable, current audience composition data. At these events, Solar Thera will market its products and services to reach a wide range of qualified consumers.

Solar Thera will ensure that all marijuana products that are provided for sale to consumers are sold in tamper or child-resistant packaging. Packaging for marijuana products sold or displayed for consumers, including any label or imprint affixed to any packaging containing marijuana products or any exit packages, will not be attractive to minors.

Packaging for marijuana products sold or displayed for consumers in multiple servings will allow a consumer to easily perform the division into single servings and include the following statement on the exterior of the package in a printed font that is no smaller than ten-point Times New Roman, Helvetica, or Arial, including capitalization: “INCLUDES MULTIPLE SERVINGS.” Solar Thera will not sell multiple serving beverages and each single serving of an edible marijuana product contained in a multiple-serving package will be marked, stamped, or otherwise imprinted with the symbol issued by the Commission under 935 CMR

500.105(5) that indicates that the single serving is a marijuana product. At no point will an individual serving size of any marijuana product contain more than five (5) milligrams of delta-nine tetrahydrocannabinol.

5.4 Logo

Solar Thera has developed a logo to be used in labeling, signage, and other materials such as letterhead and distributed materials. The logo is discreet, unassuming, and does not use medical symbols, images of marijuana, related paraphernalia, or colloquial references to cannabis or marijuana.

6. FINANCIAL PROJECTIONS

	First Full Fiscal Year Projections 2020	Second Full Fiscal Year Projections 2021	Third Full Fiscal Year Projections 2022
Projected Revenue	\$ 21,626,102	\$ 20,042,406	\$ 18,445,694
Projected Expenses	\$ 11,375,348	\$ 10,812,857	\$ 10,245,683
Total Unique Customers	22,181	22,269	22,359
Total Number of Visits	266,172	267,228	268,308
Projected Visit Growth Rate	-	4%	4%
Estimated Purchased Ounces per Visit	0.25	0.25	0.25
Estimated Price per Ounce	\$ 325.00	\$ 300.00	\$ 275.00
Total FTEs on Staff	40	40	40
Total inventory for the year (lbs.)	4506	4524	4541
Total sold for the year (lbs.)	4159	4176	4192
Total left for roll over (lbs.)	347	348	349

7. TEAM

Solar Thera has put together a team to implement the operations of the dispensary. Solar Thera intends to create 40 - 45 full and part time staff positions within the first three years of operations in Seekonk. No individual on the Solar Thera team is a controlling individual with more than three licenses in a particular class of license and no manager, director, officer, investor, or other individual affiliated with the company has been convicted of any criminal disqualifying conditions, offenses, and violations pursuant to 935 CMR 500.

Edward Dow III: (Chief Executive Officer and Chief Operating Officer)

Edward is a graduate of the University of New Hampshire and is actively pursuing his Master's in Business at the University of Massachusetts. Edward has a diverse professional background, ranging from engineering, sales management, and corporate management.

Currently, Edward steers Dow Capital Partners, an investment firm comprised of a diverse group of professionals that controls over \$10 million in assets. He also directs Solar Therapeutics, an innovative 67,000 square foot marijuana establishment that will supply both medical and recreational marijuana products upon completion of build-out. Solar Therapeutics is designed based on all industry best-practices while employing extensive green-initiative equipment including solar fields, natural gas cogeneration units, as well as battery storage and rainwater collection. There are no known comparable grow facilities within the country.

Edward has an extensive engineering background, formerly working for Woods Hole Oceanographic Institution (WHOI). Originally an engineering assistant at the Advanced Engineering Labs, he was responsible for managing production and build schedule for commercial sensors and instrumentation. Duties evolved to design and lead to his eventual title of Engineer with the Deep Submergence Laboratory (DSL). At DSL, Edward was able to travel the world mobilizing ROV Jason, a remotely operated underwater vehicle.

While designing parts and equipment at WHOI, Edward realized a supply gap within the engineered metal finishing space. It was clear that engineers were specifying technical anodized finishes requiring tighter tolerances than local industry provided. It was then Edward began the design and construction of Bay State Metal Finishing (BSM) in January 2012. BSM provides engineered metal finishes used within multiple high-tech industries including oceanography, aeronautics, and automated machinery. Duties involved design and construction of an industrial processing facility while working with all relevant local and federal zoning authorities, permitting boards, along with engineers, contractors, and local municipalities. Edward also ran the daily operations of the business.

Additionally, Edward completed a year-long corporate management training program, and subsequently worked in all aspects of commercial sales within the construction industry for Wolseley PLC (Now Ferguson PLC) for the next two years prior to WHOI.

Edward will leverage his multi-faceted experience to implement the strategy and operations of Solar Therapeutics.

Robert Keller: (Chief Financial Officer)

Mr. Robert Keller shall serve as the Chief Financial Officer. He is a founding member of Patriot Capital LLC started in 2016. Patriot Capital is a private equity firm established to fund the expansion of state licensed marijuana cultivation and dispensing operations. Mr. Keller and Patriot Capital previously sourced over 40% of the capital required to complete a \$11 million private equity deal in the Massachusetts cannabis market.

Mr. Keller earned his Associate of Arts in architecture from Dean College and his Bachelor of Science in economics from the University of Arizona in 1998. In the fall of 1998 he accepted an offer from Fidelity Investments as a financial representative which started a 15-year tenure that consisted of developing and managing Fidelity's largest book of assets under management consisting of Fidelity's highest net worth clients exceeding \$990 million. While at Fidelity Mr. Keller was recognized three times by receiving Fidelity's highest recognition for performance The Fidelity Presidents' Circle Award. This experience enabled Mr. Keller to receive extensive training in regulatory compliance, taxation, capital markets and complex investment strategies. The experience provided the foundation for him to start with UBS Financial Services in 2012 as Vice President of Wealth Management. While he was at UBS Mr. Keller managed a boutique firm of high net worth clients including the implementation of complex investment strategies, estate planning techniques, risk and tax mitigation and private equity.

In addition to his business interests, Mr. Keller has spent a considerable time pursuing charitable and community endeavors. He has been a Milford Rotarian since 2012 serving as director from 2015-2017. Milford Rotary raises and distributes over \$100,000 annually to local and international charities. Mr. Keller has also been a director at Andy's Summer Playhouse since 2014. Andy's Playhouse is a children's theater that focuses on original pieces that are written, produced and choreographed by award winning theater professionals from around the country which are then performed and managed by children. Mr. Keller has been a board member of the Town of Wilton, NH Energy Committee since 2016 assisting the town analysis energy saving strategies when remodeling the historic town hall, police station and fire department including replacing new heating systems, LED upgrades and possible future municipal solar fields. Mr. Keller has also served numerous directorships and head coaching positions in multiple town and AAU baseball organizations over a ten year youth coaching career. He currently resides with his wife of sixteen years and three children.

Michael Allen: (Chief of Security)

Mr. Michael Allen is an FBI National Academy graduate with over 30 years of law

enforcement experience. Fully accountable for staffing, budgeting, policies, procedures, integration, implementation, and overall crime prevention through a variety of means to include Community Policing, Crime Analysis and CompStat. Crime reduction strategies in 2015 that resulted in a 35% reduction in overall property crime (63% reduction in Shoplifting) and a 118% increase in drug related arrests. Worked collaboratively with Frisbie Hospital in 2016 to implement a new Recovery Center in Rochester, New Hampshire in conjunction with a Community Access to Recovery program in the police department on a 24/7 basis. Worked collaboratively with Frisbie Hospital to implement the first Narcan administration program for police officers in the State of New Hampshire. Worked collaboratively with the Rochester School Department to introduce L.E.A.D (a new substance abuse prevention/education program for youth) in grades 3, 6 and 9. Designed and implemented the departments first formal Strategic Plan.

8. FINAL REMARKS

We are a local community-focused partner first, an experienced, professional operator second. In addition to partnering on favorable host community agreements, Solar Therapeutics prides itself on maintaining a demonstrable track record of seeking out high-impact charitable donations and volunteering opportunities within the local communities in which we have the pleasure of operating.

Our company is dedicated to promoting equity in its operations for diverse populations, such as minorities, women, veterans, people with disabilities , and people of all gender identities and sexual orientations and, Solar Thera makes commitments in spirit and practice to prioritize hiring and doing business locally by proactively prioritizing members of the Seekonk community in hiring and selecting vendors to support operations.

The legal cannabis market promises to be one of the fastest growing industries in the state and Solar Thera is prepared to position itself as a market leader in the Town of Seekonk. We welcome the opportunity to better understand your goals and objectives for this emerging industry and invite you to visit our state-of-the-art facility in Somerset.

1400 Brayton Point Road
Somerset, Massachusetts 02725

(603) 498-6326 • WWW.SOLARTHERA.COM



Plan for Obtaining Liability Insurance

Solar Therapeutics Inc. (“Solar Thera”) plans to contract with Nationwide to maintain general liability insurance coverage for no less than \$1,000,000 per occurrence and \$2,000,000 in aggregate annually and product liability coverage for no less than \$1,000,000 per occurrence & \$2,000,000 in aggregate annually. The policy deductible will be no higher than \$5,000 per occurrence. Solar Thera will consider additional coverage based on availability & cost-benefit analysis. If adequate coverage is unavailable at a reasonable rate, Solar Thera will place in escrow at least \$250,000 to be expended for liabilities coverage. Any withdrawal from such escrow replenished within 10 business days. Solar Thera will keep reports documenting compliance with 935 CMR 500.105(10).



Plan for Separating Recreational from Medical Operations

Solar Therapeutics Inc. (“Solar Thera”) has developed plans to ensure virtual and physical separation between medical and adult use marijuana operations in accordance with 935 CMR 500.101(2)(e)(4).

Using a sophisticated and customized seed-to-sale and Point of Sale (POS) software system approved by the Commission, Solar Thera will virtually separate medical and adult-use operations by designating at the point of sale whether a particular marijuana product is intended for sale to a registered patient/caregiver or a verified consumer 21 years of age or older. All inventory and sales transactions will be carefully tracked and documented in these software systems.

In compliance with 935 CMR 500.140(10), Solar Thera will ensure that registered patients have access to a sufficient quantity and variety of marijuana and marijuana products to meet their medical needs at Solar Thera’s retail establishments (if granted separate licenses by the Commission). For the first 6 months of operations, 35% of Solar Thera’s marijuana product inventory will be marked for medical use and reserved for registered patients. Thereafter, a quantity and variety of marijuana products for patients that is sufficient to meet the demand indicated by an analysis of sales data collected during the preceding 6 months will be marked and reserved for registered patients.

Marijuana products reserved for registered patients will be either: (1) maintained on site in an area separate from marijuana products intended for adult use, or (2) easily accessible at another Solar Thera location and transferable to Solar Thera’s retailer location within 48 hours. Solar Thera may transfer a marijuana product reserved for medical use to adult use within a reasonable period of time prior to the product’s date of expiration.

In addition to virtual separation, Solar Thera will provide for physical separation between the area designated for sales of medical marijuana products to patients/caregivers, and the area designated for sales of adult-use marijuana products to individuals 21 years of age or older. Within the sales area, a temporary or semi-permanent barrier, such as a stanchion or other divider, will be installed to create separate, clearly marked lines for patients/caregivers and adult-use consumers. Trained marijuana establishment agents will verify the age of all individuals, as well as the validity of any Medical Use of Marijuana Program ID Cards, upon entry to the facility and direct them to the appropriate queue.

Access to the adult-use marijuana queue will be limited to individuals 21 years of age or older, regardless if the individual is registered as a patient/caregiver. Registered patients under the age of 21 will only have access to the medical marijuana queue. Registered patients/caregivers 21 years of age or older will be permitted to access either queue and will not be limited only to the medical marijuana queue.

Solar Thera will have a private area separate from the sales floor to allow a registered patient/caregiver to meet with a trained marijuana establishment agent for confidential consultations about the medical use of marijuana.

More specifically, separation measures include policies and procedures requiring that:

- If co-locating Medical and Adult Use, Solar Thera shall provide a separate area for confidential patient consultation and the signage shall state, “Consultation Area” per *935 CMR 502.140*
- After Solar Thera has been dispensing for a period of six months or longer, the company shall maintain a quantity and variety of marijuana for patients that meets the demand indicated by an analysis of sales data collected during the preceding six months in accordance with *935 CMR 500.140(6)*. *935 CMR 502.140*
- Marijuana products reserved for patient supply shall, unless unreasonably impracticable, reflect the actual types and strains of marijuana products documented during the previous six months. In the event that a substitution must be made, the substitution shall reflect the type and strain no longer available at the retailer as closely as possible per *935 CMR 502.140*
- Solar Thera shall submit to the Commission a quarterly inventory plan to reserve a sufficient quantity and variety of marijuana for registered patients. On each occasion that the reserved patient supply is exhausted, and a reasonable substitution cannot be made, the retailer shall submit a report to the Commission per *935 CMR 502.140*
- Solar Thera shall perform audits of patient supply available at the establishment on a weekly basis and retain those records for a period of six months per *935 CMR 502.140*
- Solar Thera may transfer marijuana products reserved for medical-use to adult-use within a reasonable period of time prior to the date of expiration provided that the product does not pose a risk to health or safety per *935 CMR 502.140*
- Solar Thera shall use best efforts to prioritize patient and caregiver identification verification and physical entry into its retail area per *935 CMR 502.140*



Plan for Restricting Access to Age 21 and Older

Pursuant to 935 CMR 500.050(5)(b), Solar Therapeutics Inc. will only be accessible to consumers 21 years of age or older with a verified and valid, government- issued photo ID. Upon entry in to the premises of the marijuana establishment by an individual, a Solar Therapeutics' Agent will immediately inspect the individual's proof of identification and determine the individual's age, in accordance with 935 CMR 500.140(2).

In the event Solar Therapeutics discovers any of its agents intentionally or negligently sold marijuana to an individual under the age of 21, the agent will be immediately terminated and the Commission will be promptly notified, pursuant to 935 CMR 500.105(1)(l). Solar Therapeutics will not hire any individuals who are under the age of 21 or who have been convicted of distribution of controlled substances to minors, pursuant to 935 CMR 500.030(1).

Pursuant to 935 CMR 500.105(4), Solar Therapeutics will not engage in any marketing, advertising or branding practices that are targeted to, deemed to appeal to or portray minors under the age of 21. Solar Therapeutics will not engage in any advertising, marketing and branding by means of television, radio, internet, mobile applications, social media, or other electronic communication, billboard or other outdoor advertising, including charitable, sporting or similar events, unless at least 85% of the audience is reasonably expected to be 21 years of age or older as determined by reliable and current audience composition data. Solar Therapeutics will not manufacture or sell any edible products that resemble a realistic or fictional human, animal or fruit, including artistic, caricature or cartoon renderings, pursuant to 935 CMR 500.150(1)(b). In accordance with 935 CMR 500.105(4)(a)(5), any marketing, advertising and branding materials for public viewing will include a warning stating, **“This product has not been analyzed or approved by the FDA. There is limited information on the side effects of using this product, and there may be associated health risks. Marijuana use during pregnancy and breast-feeding may pose potential harms. It is against the law to drive or operate machinery when under the influence of this product. KEEP THIS PRODUCT AWAY FROM CHILDREN.”** Pursuant to 935 CMR 500.105(6)(b), Solar Therapeutics' packaging for any marijuana or marijuana products will not use bright colors, resemble existing branded products, feature cartoons or celebrities commonly used to market products to minors, feature images of minors or other words that refer to products commonly associated with minors or otherwise be attractive to minors. Solar Therapeutics' website will require all online visitors to verify they are 21 years of age or older prior to accessing the website, in accordance with 935 CMR 500.105(4)(b)(13).



Quality Control and Testing

Quality Control

Solar Therapeutics INC. will comply with the following sanitary requirements:

1. Any Solar Therapeutics' Agent whose job includes contact with marijuana or nonedible marijuana products, is subject to the requirements for food handlers specified in 105 CMR 300.000, and all edible marijuana products will be prepared, handled, and stored in compliance with the sanitation requirements in 105 CMR 500.000, and with the requirements for food handlers specified in 105 CMR 300.000.
2. Any Solar Therapeutics' Agent working in direct contact with preparation of marijuana or nonedible marijuana products will conform to sanitary practices while on duty, including:
 - a. Maintaining adequate personal cleanliness; and
 - b. Washing hands thoroughly in an adequate hand-washing area before starting work, and at any other time when hands may have become soiled or contaminated.
3. Solar Therapeutics' hand-washing facilities will be adequate and convenient and will be furnished with running water at a suitable temperature. Hand-washing facilities will be located in Solar Therapeutics where good sanitary practices require employees to wash and sanitize their hands, and will provide effective hand-cleaning and sanitizing preparations and sanitary towel service or suitable drying devices;
4. Solar Therapeutics' facility will have sufficient space for placement of equipment and storage of materials as is necessary for the maintenance of sanitary operations;
5. Solar Therapeutics will ensure that litter and waste is properly removed and disposed of so as to minimize the development of odor and minimize the potential for the waste attracting and harboring pests. The operating systems for waste disposal will be maintained in an adequate manner pursuant to 935 CMR 500.105(12);
6. Solar Therapeutics' floors, walls, and ceilings will be constructed in such a manner that they may be adequately kept clean and in good repair;
7. Solar Therapeutics' facility will have adequate safety lighting in all processing and storage areas, as well as areas where equipment or utensils are cleaned;
8. Solar Therapeutics' buildings, fixtures, and other physical facilities will be maintained in a sanitary condition;
9. Solar Therapeutics will ensure that all contact surfaces, including utensils and equipment, will be maintained in a clean and sanitary condition. Such surfaces will be cleaned and sanitized as frequently as necessary to protect against contamination, using a sanitizing agent registered by the US Environmental Protection Agency (EPA), in accordance with labeled instructions. Equipment and utensils will be so designed and of such material and workmanship as to be adequately cleanable;

10. All toxic items will be identified, held, and stored in a manner that protects against contamination of marijuana products;
11. Solar Therapeutics will ensure that its water supply is sufficient for necessary operations, and that such water supply is safe and potable;
12. Solar Therapeutics' plumbing will be of adequate size and design, and adequately installed and maintained to carry sufficient quantities of water to required locations throughout the marijuana establishment. Plumbing will properly convey sewage and liquid disposable waste from the marijuana establishment. There will be no cross-connections between the potable and waste water lines;
13. Solar Therapeutics will provide its employees with adequate, readily accessible toilet facilities that are maintained in a sanitary condition and in good repair;
14. Solar Therapeutics will hold all products that can support the rapid growth of undesirable microorganisms in a manner that prevents the growth of these microorganisms; and
15. Solar Therapeutics will store and transport finished products under conditions that will protect them against physical, chemical, and microbial contamination, as well as against deterioration of finished products or their containers.

Solar Therapeutics' vehicles and transportation equipment used in the transportation of marijuana products or edibles requiring temperature control for safety will be designed, maintained, and equipped as necessary to provide adequate temperature control to prevent the marijuana products or edibles from becoming unsafe during transportation, consistent with applicable requirements pursuant to 21 CFR 1.908(c).

Solar Therapeutics will ensure that Solar Therapeutics' facility is always maintained in a sanitary fashion and will comply with all applicable sanitary requirements.

Solar Therapeutics will follow established policies and procedures for handling voluntary and mandatory recalls of marijuana products. Such procedures are sufficient to deal with recalls due to any action initiated at the request or order of the Commission, and any voluntary action by Solar Therapeutics to remove defective or potentially defective marijuana products from the market, as well as any action undertaken to promote public health and safety.

Any inventory that becomes outdated, spoiled, damaged, deteriorated, mislabeled, or contaminated will be disposed of in accordance with the provisions of 935 CMR 500.105(12), and any such waste will be stored, secured, and managed in accordance with applicable state and local statutes, ordinances, and regulations.

Solar Therapeutics will not sell or otherwise market marijuana or marijuana products that are not capable of being tested by Independent Testing Laboratories, except as allowed under 935CMR 500.000. No marijuana product will be sold or otherwise marketed for adult use that has not first been tested by an Independent Testing Laboratory and deemed to comply with the standards required under 935 CMR 500.160. Testing of Solar Therapeutics' marijuana products will be performed by an Independent Testing Laboratory in

compliance with the Protocol for Sampling and Analysis of Finished Medical Marijuana Products and Marijuana-infused Products, as amended in November 2016, published by the DPH.

Testing of Solar Therapeutics' environmental media will be performed in compliance with the Protocol for Sampling and Analysis of Environmental Media for Massachusetts Registered Medical Marijuana Dispensaries published by the DPH.

Solar Therapeutics' policy of responding to laboratory results that indicate contaminant levels are above acceptable limits established in the DPH protocols identified in 935 CMR 500.160(1) include notifying the Commission within 72 hours of any laboratory testing results indicating that the contamination cannot be remediated and disposing of the production batch. Such notification will describe a proposed plan of action for both the destruction of the contaminated product and the assessment of the source of contamination.

Solar Therapeutics will maintain testing results in compliance with 935 CMR 500.000 *et seq* and the record keeping policies described herein and will maintain the results of all testing for no less than one year.

All transportation of marijuana to and from Independent Testing Laboratories providing marijuana testing services will comply with 935 CMR 500.105(13). All storage of Solar Thera's marijuana at a laboratory providing marijuana testing services will comply with 935 CMR 500.105(11). All excess marijuana will be disposed in compliance with 935 CMR 500.105(12), either by the Independent Testing Laboratory returning excess marijuana to Solar Thera for disposal or by the Independent Testing Laboratory disposing of it directly.



Recordkeeping Procedures

General Overview

Solar Therapeutics Inc. has established policies regarding recordkeeping and record-retention in order to ensure the maintenance, safe keeping, and accessibility of critical documents. Electronic and wet signatures are accepted forms of execution of Solar Therapeutics documents. Records will be stored at Solar Therapeutics in a locked room designated for record retention. All written records will be available for inspection by the Commission upon request.

Recordkeeping

To ensure that Solar Therapeutics is keeping and retaining all records as noted in this policy, reviewing Corporate Records, Business Records, and Personnel Records to ensure completeness, accuracy, and timeliness of such documents will occur as part of Solar Therapeutics' quarter-end closing procedures. In addition, Solar Therapeutics' operating procedures will be updated on an ongoing basis as needed and undergo a review by the executive management team on an annual basis.

- **Corporate Records**: are defined as those records that require, at a minimum, annual reviews, updates, and renewals, including:
 - Insurance Coverage:
 - Directors & Officers Policy
 - Product Liability Policy
 - General Liability Policy
 - Umbrella Policy
 - Workers Compensation Policy
 - Employer Professional Liability Policy
 - Third-Party Laboratory Contracts
 - Commission Requirements:
 - Annual Agent Registration
 - Annual Marijuana Establishment Registration
 - Local Compliance:
 - Certificate of Occupancy
 - Special Permits
 - Variances
 - Site Plan Approvals
 - As-Built Drawings
 - Corporate Governance:
 - Annual Report
 - Secretary of State Filings
- **Business Records**: Records that require ongoing maintenance and updates. These records can be electronic or hard copy (preferably electronic) and at minimum include:
 - Assets and liabilities;
 - Monetary transactions;
 - Books of accounts, which will include journals, ledgers, and

- supporting documents, agreements, checks, invoices, and vouchers;
 - Sales records including the quantity, form, and cost of marijuana products;
 - Salary and wages paid to each agent, and any executive compensation, bonus, benefit, or item of value paid to any individual affiliated with Solar Therapeutics, including members, if any.
- Personnel Records: At a minimum will include:
 - Job descriptions for each agent and volunteer position, as well as organizational charts consistent with the job descriptions;
 - A personnel record for each marijuana establishment agent. Such records will be maintained for at least twelve (12) months after termination of the agent’s affiliation with Solar Therapeutics and will include, at a minimum, the following:
 - All materials submitted to the Commission pursuant to 935 CMR 500.030(2);
 - Documentation of verification of references;
 - The job description or employment contract that includes duties, authority, responsibilities, qualifications, and supervision;
 - Documentation of all required training, including training regarding privacy and confidentiality requirements, and the signed statement of the individual indicating the date, time, and place he or she received said training and the topics discussed, including the name and title of presenters;
 - Documentation of periodic performance evaluations; and
 - A record of any disciplinary action taken.
 - Notice of completed responsible vendor and eight-hour related duty training.
 - A staffing plan that will demonstrate accessible business hours and safe cultivation conditions;
 - Personnel policies and procedures; and
 - All background check reports obtained in accordance with 935 CMR 500.030.
- Handling and Testing of Marijuana Records
 - Solar Therapeutics will maintain the results of all testing for a minimum of one (1) year.
- Inventory Records
 - The record of each inventory will include, at a minimum, the date of the inventory, a summary of the inventory findings, and the names, signatures, and titles of the agents who conducted the inventory.
- Seed-to-Sale Tracking Records
 - Solar Thera will use a POS Software to maintain real-time inventory. The POS Software inventory reporting meets the requirements specified by the Commission and 935 CMR 500.105(8)(c) and (d), including, at a minimum, an inventory of marijuana plants; marijuana plant seeds and clones in any phase of development such as propagation, vegetation, flowering; marijuana ready for

dispensing; all marijuana products; and all damaged, defective, expired, or contaminated marijuana and marijuana products awaiting disposal.

- Inventory records will include, at a minimum, the date of the inventory, a summary of the inventory findings, and the names, signatures, and titles of the individuals who conducted the inventory.
- Incident Reporting Records
 - Within ten (10) calendar days, Solar Therapeutics will provide written notice to the Commission of any incident described in 935 CMR 500.110(7)(a), by submitting an incident report, detailing the incident, the investigation, the findings, resolution (if any), confirmation that the Police Department and Commission were notified within twenty-four (24) hours of discovering the breach, and any other relevant information. Reports and supporting documents, including photos and surveillance video related to a reportable incident will be maintained by Solar Therapeutics for no less than one year or the duration of an open investigation, whichever is longer, and made available to the Commission and law enforcement authorities upon request.
- Visitor Records
 - A visitor sign-in and sign-out record will be maintained at the security office. The record will include the visitor's name, address, organization or firm, date, time in and out, and the name of the authorized agent who will be escorting the visitor.
- Waste Disposal Records
 - When marijuana or marijuana products are disposed of, Solar Therapeutics will create and maintain a written record of the date, the type and quantity disposed of or handled, the manner of disposal or other handling, the location of disposal or other handling, and the names of the two Solar Therapeutics agents present during the disposal or handling, with their signatures. Solar Therapeutics will keep disposal records for at least three (3) years. This period will automatically be extended for the duration of any enforcement action and may be extended by an order of the Commission.
- Security Records
 - A current list of authorized agents and service personnel that have access to the surveillance room will be available to the Commission upon request.
 - Twenty-four (24) hour recordings from all video cameras that are available for immediate viewing by the Commission upon request and that are retained for at least ninety (90) calendar days.
- Transportation Records
 - Solar Therapeutics will retain all shipping manifests for a minimum of one (1) year and make them available to the Commission upon request.
- Agent Training Records
 - Documentation of all required training, including training regarding privacy and confidentiality requirements, and a signed statement of the

individual indicating the date, time, and place he or she received the training, the topics discussed and the name and title of the presenter(s).

- Closure
 - In the event Solar Therapeutics closes, all records will be kept for at least two (2) years at Solar Therapeutics' expense in a form (electronic, hard copies, etc.) and location acceptable to the Commission. In addition, Solar Therapeutics will communicate with the Commission during the closure process and accommodate any additional requests the Commission or other agencies may have.
- Written Operating Policies and Procedures: Policies and Procedures related to Solar Therapeutics' operations will be updated on an ongoing basis as needed and undergo a review by the executive management team on an annual basis. Policies and Procedures will include the following:
 - Security measures in compliance with 935 CMR 500.110;
 - Agent security policies, including personal safety and crime prevention techniques;
 - A description of Solar Therapeutics' hours of operation and after-hours contact information, which will be provided to the Commission, made available to law enforcement officials upon request, and updated pursuant to 935 CMR 500.000.
 - Storage of marijuana in compliance with 935 CMR 500.105(11);
 - Description of the various strains of marijuana to be cultivated, processed or sold, as applicable, and the form(s) in which marijuana will be dispensed;
 - Procedures to ensure accurate recordkeeping, including inventory protocols in compliance with 935 CMR 500.160;
 - Plans for quality control, including product testing for contaminants in compliance with 935 CMR 500.160;
 - A staffing plan and staffing records in compliance with 935 CMR 500.105(9);
 - Emergency procedures, including a disaster plan with procedures to be followed in case of fire or other emergencies;
 - Alcohol, smoke, and drug-free workplace policies;
 - A plan describing how confidential information will be maintained;
 - Policy for the immediate dismissal of any dispensary agent who has:
 - Diverted marijuana, which will be reported the Police Department and to the Commission;
 - Engaged in unsafe practices with regard to Solar Therapeutics' operations, which will be reported to the Commission; or
 - Been convicted or entered a guilty plea, plea of *nolo contendere*, or admission to sufficient facts of a felony drug offense involving distribution to a minor in the Commonwealth, or a like violation of the laws of another state, the United States or a foreign jurisdiction, or a military, territorial, or Native American tribal authority.

- A list of all executives of Solar Therapeutics, and members, if any, of the licensee must be made available upon request by any individual.
935 CMR 500.105(1)(m) requirement may be fulfilled by placing this information on Solar Therapeutics' website.
- Policies and procedures for the handling of cash on Solar Therapeutics' premises including but not limited to storage, collection frequency and transport to financial institution(s).
- Policies and procedures to prevent the diversion of marijuana to individuals younger than 21 years old.
- Policies and procedures for energy efficiency and conservation that will include:
 - Identification of potential energy use reduction opportunities (including but not limited to natural lighting, heat recovery ventilation and energy efficiency measures), and a plan for implementation of such opportunities;
 - Consideration of opportunities for renewable energy generation, including, where applicable, submission of building plans showing where energy generators could be placed on site, and an explanation of why the identified opportunities were not pursued, if applicable;
 - Strategies to reduce electric demand (such as lighting schedules, active load management and energy storage); and
 - Engagement with energy efficiency programs offered pursuant to M.G.L. c. 25 § 21, or through municipal lighting plants.

Record-Retention

Solar Therapeutics will meet Commission recordkeeping requirements and retain a copy of all records for two (2) years, unless otherwise specified in the regulations.



Maintaining of Financial Records

Solar Therapeutics Inc.'s operating policies and procedures ensure financial records are accurate and maintained in compliance with the Commission's Adult Use of Marijuana regulations (935 CMR 500). Financial records maintenance measures include policies and procedures requiring that:

- Confidential information will be maintained in a secure location, kept separate from all other records, and will not be disclosed without the written consent of the individual to whom the information applies, or as required under law or pursuant to an order from a court of competent jurisdiction; provided however, the Commission may access this information to carry out its official duties.
- All recordkeeping requirements under 935 CMR 500.105(9) are followed, including:
 - Keeping written business records, available for inspection, and in accordance with generally accepted accounting principles, which will include manual or computerized records of:
 - Assets and liabilities;
 - Monetary transactions;
 - Books of accounts, which will include journals, ledgers, and supporting documents, agreements, checks, invoices, and vouchers;
 - Sales records including the quantity, form, and cost of marijuana products; and
 - Salary and wages paid to each employee and any executive compensation, bonus, benefit, or item of value paid to any individual affiliated with a marijuana establishment, including members, if any.
- All sales recording requirements under 935 CMR 500.140(6) are followed, including:
 - Utilizing a point-of-sale (POS) system approved by the Commission, in consultation with the DOR, and a sales recording module approved by DOR;
 - Conducting a monthly analysis of its equipment and sales date, and maintaining records, available to the Commission upon request, that the monthly analysis has been performed;
 - Complying with 830 CMR 62C.25.1: *Record Retention* and DOR Directive 16-1 regarding recordkeeping requirements;
 - Adopting separate accounting practices at the point-of-sale for marijuana and marijuana product sales, and non-marijuana sales;
 - Maintaining such records that would allow for the Commission and the DOR to audit and examine the point-of-sale system used in order to ensure compliance with Massachusetts tax laws and 935 CMR 500; and
- Additional written business records will be kept, including, but not limited

to, records of:

- Compliance with liability insurance coverage or maintenance of escrow requirements under 935 CMR 500.105(10) and all bond or escrow requirements under 935 CMR 500.105(16);
- Fees paid under 935 CMR 500.005 or any other section of the Commission's regulations; and
- Fines or penalties, if any, paid under 935 CMR 500.550 or any other section of the Commission's regulations.



Qualifications and Training

Solar Therapeutics Inc. will ensure that all employees hired to work at a Solar Therapeutics' facility will be qualified to work as a marijuana establishment agent and properly trained to serve in their respective roles in a compliant manner.

Qualifications

In accordance with 935 CMR 500.030, a candidate for employment as a marijuana establishment agent must be 21 years of age or older. In addition, the candidate cannot have been convicted of a criminal offense in the Commonwealth involving the distribution of controlled substances to minors, or a like violation of the laws of another state, the United States, or foreign jurisdiction, or a military, territorial, or Native American tribal authority.

Solar Therapeutics will also ensure that its employees are suitable for registration consistent with the provisions of 935 CMR 500.802. In the event that Solar Therapeutics discovers any of its agents are not suitable for registration as a marijuana establishment agent, the agent's employment will be terminated, and Solar Therapeutics will notify the Commission within one (1) business day that the agent is no longer associated with the establishment.

Training

As required by 935 CMR 500.105(2), and prior to performing job functions, each of Solar Therapeutics' agents will successfully complete a comprehensive training program that is tailored to the roles and responsibilities of the agent's job function. Agent training will at least include the Responsible Vendor Program and eight (8) hours of on-going training annually.

On or after July 1, 2019, all of Solar Therapeutics' current owners, managers, and employees will have attended and successfully completed a Responsible Vendor Program operated by an education provider accredited by the Commission to provide the annual minimum of two hours of responsible vendor training to marijuana establishment agents. Solar Therapeutics' new, non-administrative employees will complete the Responsible Vendor Program within 90 days of the date they are hired. Solar Therapeutics' owners, managers, and employees will then successfully complete the program once every year thereafter. Solar Therapeutics will also encourage administrative employees who do not handle or sell marijuana to take the responsible vendor program on a voluntary basis to help ensure compliance. Solar Therapeutics' records of responsible vendor training program compliance will be maintained for at least four (4) years and made available during normal business hours for inspection by the Commission and any other state licensing authority upon request.

As part of the Responsible Vendor program, Solar Therapeutics' agents will receive training on a variety of topics relevant to marijuana establishment operations, including but not limited to the following:

1. Marijuana's effect on the human body, including physical effects based on different types of marijuana products and methods of administration, and

- recognizing the visible signs of impairment;
2. Best practices for diversion prevention and prevention of sales to minors;
 3. Compliance with tracking requirements;
 4. Acceptable forms of identification, including verification of valid photo identification and medical marijuana registration and confiscation of fraudulent identifications;
 5. Such other areas of training determined by the Commission to be included; and
 6. Other significant state laws and rules affecting operators, such as:
 - Local and state licensing and enforcement;
 - Incident and notification requirements;
 - Administrative and criminal liability and license sanctions and court sanctions;
 - Waste disposal and health and safety standards;
 - Patrons prohibited from bringing marijuana onto licensed premises;
 - Permitted hours of sale and conduct of establishment;
 - Permitting inspections by state and local licensing and enforcement authorities;
 - Licensee responsibilities for activities occurring within licensed premises;
 - Maintenance of records and privacy issues; and
 - Prohibited purchases and practices.



Personnel Policies Including Background Checks

Overview

Solar Therapeutics Inc. will maintain personnel records as a separate category of records due to the sensitivity and importance of information concerning agents, including registration status and background check records. Solar Therapeutics shall keep, at a minimum, the following personnel records:

- Job descriptions for each employee and volunteer position, as well as organizational charts consistent with the job descriptions;
- A personnel record for each Marijuana Establishment Agent;
- A staffing plan that will demonstrate accessible business hours and safe conditions;
- Personnel policies and procedures; and
- All background check reports obtained in accordance with 935 CMR 500.030.

Job Descriptions

Director of Security: Under the supervision of the Chief Executive Officer, the Director of Security is responsible for the development and overall management of the Security Policies and Procedures for Solar Therapeutics, while implementing, administering, and revising the policies as needed. In addition, the Director of Security will perform the following duties:

- Provide general training to Solar Therapeutics Agents during new hire orientation or re-current trainings throughout the year;
- Provide training specific for Security Agents prior to the Security Agent commencing job functions;
- Review and approve incident reports and other reports written by Security Agents prior to submitting to the executive management team—follow up with security agent if needed;
- Maintain lists of agents authorized to access designated areas of the Solar Therapeutics' facility, including cash and product storage vaults, the surveillance and network equipment room, and other highly sensitive areas of the Solar Therapeutics' facility;
- Lead a working group comprised of the Chief Executive Officer, Director of Compliance and any other designated advisors to ensure the current policies and procedures are properly implemented, integrated, effective, and relevant to ensure the safety of Solar Therapeutics' Agents and assets;
- Ensure that all required background checks have been completed and documented prior to an agent performing job functions; ensure agent is granted appropriate level of access to the facility necessary to complete his/her job functions;
- Maintain all security-related records, incident reports and other reports written by security agents;
- Evaluate and determine the number of Security Agents assigned to each shift and proper shift change times; and

- Maintain frequent contact with local law enforcement authorities.

Security Agent: Security Agents monitor Solar Therapeutics' security systems including alarms, video surveillance, and motion detectors. Security Agents are responsible for ensuring that only authorized individuals are permitted access to the Solar Therapeutics' facility by verifying appropriate ID cards and other forms of identification.

In addition, Security Agents perform the following duties and other duties upon request:

- Investigate, communicate, and provide leadership in the event of an emergency such as an intrusion, fire, or other threat that jeopardizes customers, authorized visitors, and Solar Therapeutics' Agents;
- Respond and investigate security situations and alarm calls; clearly document the incident and details surrounding the incident in a written report for the Director of Security;
- Oversee the entrance to the facility and verify credentials of each person seeking access to the Solar Therapeutics' facility;
- Answer routine inquiries;
- Log entries, and maintain visitor log;
- Escort authorized visitors in restricted access areas; and
- Escort Solar Therapeutics' Agents from the facility during non-business hours and perform security checks at designated intervals.

Inventory Supervisor: The Inventory Supervisor is responsible for inventory on a day-to-day basis as well as the weekly and monthly inventory counts and waste disposal requirements. The Inventory Supervisor will perform the comprehensive annual inventory in conjunction with the Director of Compliance and the executive management team. Additional duties include, but are not limited to:

- Implementing inventory controls to track and account for all dispensary inventory;
- Implementing procedures and notification policies for proper disposal;
- Maintaining records, including operating procedures, inventory records, audit records, storage and transfer records;
- Maintaining documents with each day's beginning, acquisitions, sales, disposal, and ending inventory; and
- Proper storing, labeling, tracking, and reporting of inventory.

Inventory Specialist: Inventory Specialists support the Inventory Supervisor during day-to-day operations. Responsibilities include, but are not limited to:

- Maintaining records, including operating procedures, inventory records, audit records, storage and transfer records;
- Maintaining documents with each day's beginning, acquisitions, sales, disposal and ending inventory;
- Ensuring products are properly stored, labeled, and recorded in the POS Software system;
- Ensuring waste is properly stored; and

- Coordinating the waste disposal schedule and ensuring Solar Therapeutics' policies and procedures for waste disposal are adhered to.

Human Resources Manager: The Human Resources Manager at Solar Therapeutics will support the executive management team on a day-to-day basis to effectively implement all personnel policies and procedures for Solar Therapeutics, including hiring processes. The Human Resources Manager will:

- Oversee hiring and release of Solar Therapeutics' Agents.
- Review and revise Solar Therapeutics' personnel policies and procedures in consultation with the executive management team and department managers;
- Develop training schedules and policies for Solar Therapeutics' Agents under the supervision of the executive management team and department managers;
- Handle any and all agent discipline as necessary;
- Ensure compliance with any and all workplace policy laws and requirements; and
- Be responsible for such additional human resources tasks as determined by the executive management team.

Agent Personnel Records

Personnel records for each agent will be maintained for at least twelve (12) months after termination of the agent's affiliation with Solar Therapeutics and will include, at a minimum, the following:

- All materials submitted to the Commission pursuant to 935 CMR 500.030(2);
- Documentation of verification of references;
- The job description or employment contract that includes duties, authority, responsibilities, qualifications, and supervision;
- Documentation of all required training, including training regarding privacy and confidentiality requirements, and the signed statement of the individual indicating the date, time, and place he or she received said training and the topics discussed, including the name and title of presenters;
- Documentation of periodic performance evaluations;
- A record of any disciplinary action taken;
- Notice of completed responsible vendor and eight-hour related duty training;
- Results of initial background investigation, including CORI reports; and
- Documentation of all security related events (including violations) and the results of any investigations and description of remedial actions, restrictions, or additional training required as a result of an incident.

Personnel records will be kept in a secure location to maintain confidentiality and will only be accessible to the agent's manager or members of the executive management team.

Staffing Plan and Business Hours

Hiring and Recruitment

Solar Therapeutics' Human Resource Manager will engage the executive management team and management staff on a regular basis to determine if vacancies are anticipated and whether specific positions need to be created in response to company needs. Solar Therapeutics' personnel practices will comply with the following, which will apply to all types of employment situations, including, but not limited to, hiring, terminations, promotions, training, wages and benefits:

- State anti-discrimination statutes and Equal Employment Opportunity Commission (EEOC) requirements;
- Solar Therapeutics' Diversity Plan and Community Initiatives;
- Solar Therapeutics' Plan to Positively Impact Areas of Disproportionate Impact;
- Background Checks and References;
- Mandatory reporting of criminal convictions (and termination if necessary);
- State and Federal Family Leave Act;
- Workplace Safety Laws;
- Workers' Compensation;
- State and Federal Minimum Wage Requirements;
- Non-Disclosure and Non-Complete Agreements; and
- Any other applicable local, state, or federal employment laws, rules, or regulations.

Standards of Conduct

Solar Therapeutics is committed to maintaining an environment conducive to the health and well-being of customers and employees. It is Solar Therapeutics' mission to provide a professional workplace free from harassment and discrimination for employees. Solar Therapeutics shall not tolerate harassment or discrimination on the basis of sex, race, color, national origin, age, religion, disability, sexual orientation, gender identity, gender expression, or any other trait or characteristic protected by any applicable federal, state, or local law or ordinance. Harassment or discrimination on the basis of any protected trait or characteristic is contrary to Solar Therapeutics' values and is a violation of the Company Code of Conduct. Harassment is a form of discrimination. There is a broad range of behavior that could constitute harassment. In general, harassment is any verbal or physical conduct that:

- Has the purpose or effect of creating an intimidating, hostile, or offensive working environment;
- Has the purpose or effect of unreasonably interfering with an individual's work performance; or
- Adversely affects an individual's employment opportunities.

Employees are expected to maintain the highest degree of professional behavior. Any harassment or discrimination by employees is strictly prohibited. Further, harassing or discriminatory behavior of non-employees directed at Solar Therapeutics' employees or customers is also condemned and will be promptly addressed.

Violence and Weapons in the Workplace

Any and all acts of violence in the workplace will result in immediate dismissal of the employee, customer, or parties involved. Law enforcement will be contacted immediately in the case of a violent event. Weapons are not permitted to be brought on site by employees, customers, or other parties. Any employee found carrying a weapon on the premises of a Solar Therapeutics' facility will be immediately terminated, and any customer found carrying a weapon on the premises will be asked to leave and/or the police will be notified accordingly.

At-Will Employment

In the state of Massachusetts, employment is assumed to be at-will unless otherwise stated. At-will employment implies that employer and employee alike may terminate the work relationship at any given moment and for any legitimate purpose. Wrongful termination may be more difficult to prove in an at-will arrangement because of the freedom that each party has to end the employment. However, there are still many instances wherein a termination or discharge can be called wrongful, even in an at-will employment.

Workplace Attire

The required attire for registered agents at Solar Therapeutics varies based upon required duties. New hire training and the onboarding process will go over the workplace attire specific to each role and the department manager will be responsible for ensuring compliance with all requirements is met.

Business Hours

Monday: 9:00 a.m. - 11:00 p.m.
Tuesday: 9:00 a.m. - 11:00 p.m.
Wednesday: 9:00 a.m. - 11:00 p.m.
Thursday: 9:00 a.m. - 11:00 p.m.
Friday: 9:00 a.m. - 11:00 p.m.
Saturday: 9:00 a.m. - 11:00 p.m.
Sunday: 10:00 a.m. - 11:00 p.m.

Overview of Personnel Policies and Procedures

Standard Employment Practices

Solar Therapeutics values the contributions of its management and staff positions. Solar Therapeutics will strive to be the industry leader in workplace satisfaction by offering highly competitive wage and benefits packages and developing a culture that values a proper work-

life balance, boasts a transparent and accessible executive management team, and fosters a work ethic that focuses on the mission of the company and spirit of the adult- use marijuana program in Massachusetts.

Advancement

The organization will be structured in a relatively flat manner, with promotional opportunities within each department. Participation in training and bi-annual performance evaluations will be critical for any promotions or pay increases.

Written Policies

Solar Therapeutics' written policies will address, inter alia, the Family and Medical Leave Act (FMLA), the Consolidated Omnibus Budget Reconciliation Act (COBRA), equal employment opportunity, discrimination, harassment, the Employee Retirement Income Security Act (ERISA), disabilities, workers' compensation, maintenance of personnel files, privacy, email policy, 935 CMR 500 et seq., holidays, hours, sick time, personal time, overtime, performance reviews, disciplinary procedures, working hours, pay rates, overtime, bonuses, veteran preferences, drug testing, personnel policies, military leaves of absence, bereavement leave, jury duty, CORI checks, smoking, HIPAA, patient confidentiality, and compliance hotline.

Investigations

Solar Therapeutics will set forth policies and procedures to investigate any complaints or concerns identified or raised internally or externally in order to stay in compliance with 935 CMR 500.000 et seq.

Designated Outside Counsel

Solar Therapeutics may retain counsel specializing in employment law to assist the Human Resources Manager with any issues and questions.

Job Status

Job Classifications

Positions at Solar Therapeutics are categorized by rank and by department. The executive management team oversees the overall success of mission of the company; the CEO is responsible for implementation of the mission and the executive management team as a whole is responsible for ensuring that all departments are properly executing their functions and responsibilities. Job classification is comprised of three rank tiers: Executive Management, Management, and Non- Management Employee.

Work Schedules

Work schedules will be either part-time, full-time, or salaried, depending of the specific position. Schedules will be set according to the needs of each department as determined by the department manager and the executive manager they report to. It is the department manager's responsibility to develop and implement a work

schedule that provides necessary duty and personnel coverage but does not exceed what is required for full implementation of operations. It is also the department manager's responsibility to ensure that adequate coverage occurs on a daily basis and does not lead to unnecessary utilization of overtime coverage.

Mandatory Meetings and Community Service Days

There will be a mandatory, reoccurring company-wide meeting on a monthly basis. All personnel will be notified if their attendance is required. Certain personnel, such as housekeeping staff, may not be required to attend. Each department will have a mandatory weekly meeting scheduled by the department manager. The department managers will provide agendas for all meetings and will report to their executive manager.

Breaks

Daily breaks, including lunch breaks, will comply with the laws of the Commonwealth.

Performance Reviews

Performance reviews will be conducted by executive or department managers. Reviews will be conducted at three-month intervals for new employees during the first year and at six-month intervals thereafter. A written synopsis must be provided to, and signed by, the employee under review. Reviews must be retained in each employee's employment file. Performance reviews must take into account positive performance factors and areas requiring improvement. Scoring systems may be utilized to help reflect an employee's overall performance.

Leave Policies

Solar Therapeutics' leave policies will comport with all state and federal statutes. All full-time employees will receive two 40-hour weeks of paid vacation per annum. Additional leave must be requested at least two weeks in advance and approved by the employee's department manager. Solar Therapeutics will determine which holidays will be observed and which departments will not be required to work. Solar Therapeutics will offer paid maternity leave. Additional leave will not be paid and must be approved by the department manager.

Solar Therapeutics anticipates observing the following holidays:

- New Year's Day;
- Martin Luther King Day;
- Presidents' Day;
- Memorial Day;
- Independence Day;
- Labor Day;
- Thanksgiving; and
- Christmas Day.

Disciplinary Policies

Purpose

Solar Therapeutics' progressive discipline policies and procedures are designed to provide a structured corrective action process to improve and prevent a recurrence of undesirable behavior and/or performance issues. The steps outlined below of Solar Therapeutics' progressive discipline policies and procedures have been designed consistent with Solar Therapeutics' organizational values, best practices, and state and federal employment laws.

Solar Therapeutics reserves the right to combine or skip steps depending upon the facts of each situation and the nature of the offense. The level of disciplinary intervention may also vary. Some of the factors that will be considered are whether the offense is repeated despite coaching, counseling, and/or training; the employee's work record; and the impact the employee's performance, conduct and/or attendance issues have on Solar Therapeutics as an organization.

Procedure

Step 1: Counseling and Verbal Warning

Step 1 creates an opportunity for the immediate supervisor to schedule a meeting with an employee to bring attention to the existing performance, conduct, or attendance issue. The supervisor should discuss with the employee the nature of the problem and/or violation of company policies and procedures. The supervisor is expected to clearly outline expectations and steps the employee must take to improve performance or resolve the problem.

Within five business days, the supervisor will prepare written documentation of a Step 1 meeting. The employee will be asked to sign the written documentation. The employee's signature is needed to demonstrate the employee's understanding of the issues and the corrective action needed.

Step 2: Written Warning

While it is hoped that the performance, conduct, or attendance issues that were identified in Step 1 have been corrected, Solar Therapeutics recognizes that this may not always be the case. A written warning involves a more formal documentation of the performance, conduct, or attendance issues and consequences.

During Step 2, the immediate supervisor and a department manager or director will meet with the employee and review any additional incidents or information about the performance, conduct, or attendance issues as well as any prior relevant corrective action plans. Management will outline the consequences for the employee of his or her continued failure to meet performance, conduct and/or attendance expectations. A formal

performance improvement plan (PIP) requiring the employee's immediate and sustained corrective action will be issued within five business days of a Step 2 meeting. A warning outlining that the employee may be subject to additional discipline up to and including termination if immediate and sustained corrective action is not taken may also be included in the PIP.

Step 3: Suspension and Final Written Warning

There may be performance, conduct, or safety incidents so problematic and harmful that the most effective action may be the temporary removal of the employee from the workplace. When immediate action is necessary to ensure the safety of the employee or others, the immediate supervisor may suspend the employee pending the results of an investigation.

Suspensions that are recommended as part of the normal progression of the progressive discipline policies and procedures are subject to approval from a next-level manager and the Human Resources Manager.

Depending upon the seriousness of the infraction, an employee may be suspended without pay in full-day increments consistent with federal, state and local wage-and-hour employment laws. Nonexempt/hourly employees may not substitute or use an accrued paid vacation or sick day in lieu of the unpaid suspension. Due to Fair Labor Standards Act (FLSA) compliance issues, unpaid suspension of salaried/exempt employees is reserved for serious workplace safety or conduct issues. The Human Resources Manager will provide guidance so that discipline is administered without jeopardizing the FLSA exemption status.

Pay may be restored to an employee if an investigation of the incident or infraction absolves the employee.

Step 4: Recommendation for Termination of Employment

The last and most serious step in the progressive discipline procedures is a recommendation to terminate employment. Generally, Solar Therapeutics shall try to utilize the progressive steps of this policy by first providing warnings, a final written warning, and/or suspension from the workplace before proceeding to a recommendation to terminate employment. However, Solar Therapeutics reserves the right to combine and skip steps depending upon the circumstances of each situation and the nature of the offense, and an employee may be terminated without prior notice or disciplinary action.

Management's recommendation to terminate employment must be approved by the Human Resources Manager and department manager or designee. Final approval may be required from the CEO or designee.

Nothing in this policy provides any contractual rights regarding employee discipline or counseling nor should anything in this policy be read or

construed as modifying or altering the employment-at-will relationship between Solar Therapeutics and its employees.

Appeal Process

Any employee subject to a disciplinary action will have the opportunity to present information on their own behalf that may challenge information management relied upon in making the decision to issue the disciplinary action. The purpose of this appeal process is to provide insight into extenuating circumstances that may have contributed to the employee's performance, conduct and/or attendance issues, while allowing for an equitable solution.

If an employee does not present information on their own behalf during a step meeting, they will have five business days after the meeting to present such information to the supervisor who conducted the meeting.

Performance and Conduct Issues Not Subject to Progressive Discipline

Behavior that is illegal is not subject to progressive discipline and may be reported to local law enforcement. Theft, intoxication at work, fighting and other acts of violence are also not subject to progressive discipline and may be grounds for immediate termination.

Documentation

Any employee subject to progressive discipline will be provided with copies of all relevant documentation related to the progressive discipline process, including all PIPs. The employee will be asked to sign copies of this documentation attesting to their receipt and understanding of the corrective action outlined in these documents. Copies of these documents will be placed in the employee's official personnel file.

Separation of Employment

Separation of employment within an organization can occur for several different reasons. Employment may end as a result of resignation, retirement, release (end of season or assignment), reduction in workforce, or termination. When an employee separates from Solar Therapeutics, the employee's supervisor must contact the Human Resources Manager to schedule an exit interview, which will typically take place on the employee's last workday.

Types of Separation

1. Resignation

Resignation is a voluntary act initiated by the employee to end employment with Solar Therapeutics. The employee must provide a minimum of two (2) weeks' notice prior to resignation. If an employee does not provide advance notice or fails to actually work the remaining two weeks, the employee will be ineligible for rehire. The resignation date must not fall on the day after a holiday.

2. Retirement

An employee who wishes to retire is required to notify their department director and the Human Resources Manager in writing at least one (1) month before planned retirement date. It is the practice of Solar Therapeutics to give special recognition to employees at the time of their retirement.

3. Job Abandonment

An employee who fails to report to work or contact their supervisor for two (2) consecutive workdays will be considered to have abandoned their job without notice effective at the end of the employee's normal shift on the second day. The department manager will notify the Human Resources Manager at the expiration of the second workday and initiate the paperwork to terminate the employee. Employees who are separated due to job abandonment are ineligible for rehire.

4. Termination

Employees of Solar Therapeutics are employed on an at-will basis, and the company retains the right to terminate an employee at any time.

5. Reduction in Workforce

An employee may be laid off due to changes in duties, organizational changes, lack of funds, or lack of work. Employees who are laid off may not appeal the layoff decision through the appeal process.

6. Release

Release is the end of temporary or seasonal employment. The Human Resources Manager, in consultation with the department manager, will inform the temporary or seasonal worker of their release according to the terms of the individual's temporary employment.

Exit Interview

The separating employee will contact the HR department as soon as notice is given to schedule an exit interview. The interview will be held on the employee's last day of work or another day, as mutually agreed upon.

Return of Property

The separating employee must return all company property at the time of separation, including but not limited to, uniforms, cell phones, keys, computers, and identification cards. Failure to return certain items may result in deductions from the employee's final paycheck. All separating employees will be required to sign a Wage Deduction Authorization Agreement, allowing Solar Thera to deduct the costs of such items from their final paycheck.

Termination of Benefits

An employee separating from Solar Therapeutics is eligible to receive benefits as long as the appropriate procedures are followed as stated above. Two weeks' notice must be given, and the employee must work the full two work weeks. Accrued vacation leave will be paid in the last paycheck. Accrued sick leave will be paid in the last paycheck.

Health Insurance

Health insurance terminates on the last day of the month of employment, unless employee requests immediate termination of benefits. Information about the Consolidated Omnibus Budget Reconciliation Act (COBRA) continued health coverage will be provided. Employees will be required to pay their share of the dependent health and dental premiums through the end of the month.

Rehire

Former employees who left in good standing and were classified as eligible for rehire may be considered for reemployment. An application must be submitted to the Human Resources Manager, and the applicant must meet all minimum qualifications and requirements of the position, including any qualifying exam, when required.

Department managers must obtain approval from the Human Resources Manager or designee prior to rehiring a former employee. Rehired employees begin benefits just as any other new employee. Previous tenure will not be considered in calculating longevity, leave accruals, or any other benefits.

An applicant or employee who is terminated for violating policy or who resigned in lieu of termination from employment due to a policy violation will be ineligible for rehire.

Compensation

As an employer, Solar Therapeutics believes that it is in the best interest of both the organization and Solar Therapeutics' employees to fairly compensate its workforce for the value of the work provided. It is Solar Therapeutics' intention to use a compensation system that will determine the current market value of a position based on the skills, knowledge, and behaviors required of a fully-competent incumbent. The system used for determining compensation will be objective and non-discriminatory in theory, application and practice. The company has determined that this can best be accomplished by using a professional compensation consultant, as needed, and a system recommended and approved by the executive management team.

Selection Criteria

1. The compensation system will price positions to market by using local, national, and industry specific survey data.

2. The market data will primarily include marijuana-related businesses and will include survey data for more specialized positions and will address significant market differences due to geographical location.
3. The system will evaluate external equity, which is the relative marketplace job worth of every marijuana industry job directly comparable to similar jobs at Solar Therapeutics, factored for general economic variances, and adjusted to reflect the local economic marketplace.
4. The system will evaluate internal equity, which is the relative worth of each job in the organization when comparing the required level of job competencies, formal training and experience, responsibility and accountability of one job to another, and arranging all jobs in a formal job-grading structure.
5. Professional support and consultation will be available to evaluate the compensation system and provide on-going assistance in the administration of the program.
6. The compensation system must be flexible enough to ensure that the company is able to recruit and retain a highly-qualified workforce, while providing the structure necessary to effectively manage the overall compensation program.

Responsibilities

The executive management team will give final approval for the compensation system that will be used by Solar Therapeutics.

1. On an annual basis the executive management team will review and approve, as appropriate, recommended changes to position-range movement as determined through the vendor's market analysis process.
2. As part of the annual budgeting process, the executive management team will review and approve, as appropriate, funds to be allocated for total compensation, which would include base salaries, bonuses, variable based or incentive-based pay, and all other related expenses, including benefit plans.

Management Responsibility

1. The CEO is charged with ensuring that Solar Therapeutics is staffed with highly-qualified, fully-competent employees and that all programs are administered within appropriate guidelines and within the approved budget.
2. The salary budget will include a gross figure for the following budget adjustments, but the individual determinations for each employee's salary adjustment will be the exclusive domain of the CEO: determining the appropriate head count, titles, position levels, merit and promotional increases and compensation consisting of salary, incentive, bonus, and other discretionary pay for all positions.
3. The CEO will ensure that salary ranges are updated at least annually, that all individual jobs are market priced at least once every two years, and that pay equity adjustments are administered in a fair and equitable manner.

Agent Background Checks

- In addition to completing the Commission's agent registration process, all agents hired to work for Solar Therapeutics will undergo a detailed background investigation prior to being granted access to a Solar Therapeutics facility or beginning work duties.
- Background checks will be conducted on all agents in their capacity as employees or volunteers for Solar Therapeutics pursuant to 935 CMR 500.100 and will be used by the Director of Security, who will be registered with the Department of Criminal Justice Information Systems pursuant to 803 CMR 2.04: iCORI Registration and the Commission for purposes of determining the suitability of individuals for registration as a marijuana establishment agent with the licensee.
- For purposes of determining suitability based on background checks performed in accordance with 935 CMR 500.101(1), Solar Therapeutics shall consider:
 - a. All conditions, offenses, and violations are construed to include Massachusetts law or like or similar law(s) of another state, the United States or foreign jurisdiction, a military, territorial or Native American tribal authority, or any other jurisdiction.
 - b. All criminal disqualifying conditions, offenses, and violations include the crimes of attempt, accessory, conspiracy, and solicitation. Juvenile dispositions will not be considered as a factor for determining suitability.
 - c. Where applicable, all look back periods for criminal conditions, offenses, and violations included in 935 CMR 500.802 commence upon the date of disposition; provided, however, that if disposition results in incarceration in any institution, the look back period will commence upon release from incarceration.
- Suitability determinations will be made in accordance with the procedures set forth in 935 CMR 500.800. In addition to the requirements established in 935 CMR 500.800, Solar Therapeutics shall:
 - a. Comply with all guidance provided by the Commission and 935 CMR 500.802: Tables B through D to determine if the results of the background are grounds for Mandatory Disqualification or Presumptive Negative Suitability Determination.
 - b. Consider whether offense(s) or information that would result in a Presumptive Negative Suitability Determination under 935 CMR 500.802. In the event a Presumptive Negative Suitability Determination is made, Solar Thera will consider the following factors:
 - i. Time since the offense or incident;
 - ii. Age of the subject at the time of the offense or incident;
 - iii. Nature and specific circumstances of the offense or incident;

- iv. Sentence imposed and length, if any, of incarceration, if criminal;
 - v. Penalty or discipline imposed, including damages awarded, if civil or administrative;
 - vi. Relationship of offense or incident to nature of work to be performed;
 - vii. Number of offenses or incidents;
 - viii. Whether offenses or incidents were committed in association with dependence on drugs or alcohol from which the subject has since recovered;
 - ix. If criminal, any relevant evidence of rehabilitation or lack thereof, such as information about compliance with conditions of parole or probation, including orders of no contact with victims and witnesses, and the subject's conduct and experience since the time of the offense including, but not limited to, professional or educational certifications obtained; and
 - x. Any other relevant information, including information submitted by the subject.
- c. Consider appeals of determinations of unsuitability based on claims of erroneous information received as part of the background check during the application process in accordance with 803 CMR 2.17: Requirement to Maintain a Secondary Dissemination Log and 2.18: Adverse Employment Decision Based on CORI or Other Types of Criminal History Information Received from a Source Other than the DCJIS.
- Upon adverse determination, Solar Therapeutics shall provide the applicant a copy of their background screening report and a pre-adverse determination letter providing the applicant with a copy of their right to dispute the contents of the report, who to contact to do so and the opportunity to provide a supplemental statement.
 - After 10 business days, if the applicant is not disputing the contents of the report and any provided statement does not alter the suitability determination, an adverse action letter will be issued providing the applicant information on the final determination made by Solar Therapeutics along with any legal notices required.
- All suitability determinations will be documented in compliance with all requirements set forth in 935 CMR 500 et seq. and guidance provided by the Commission.
- Background screening will be conducted by an investigative firm holding the National Association of Professional Background Screeners (NAPBS®) Background Screening Credentialing Council (BSCC) accreditation and capable of performing the searches required by the regulations and guidance provided by the Commission.
- References provided by the agent will be verified at the time of hire.

- As deemed necessary, individuals in key positions with unique and sensitive access (e.g. members of the executive management team) will undergo additional screening, which may include interviews with prior employers or colleagues.
- As a condition of their continued employment, agents, volunteers, contractors, and subcontractors are required to renew their Program ID cards annually and submit to other background screening as may be required by Solar Therapeutics or the Commission.

SOLAR THERAPEUTICS SEEKONK DISPENSARY



1735 FALL RIVER AVENUE - SEEKONK, MA 02771

DRAWING LIST		
SHEET NO.	DRAWING NAME	REVISION
CS	COVER SHEET	
A0.1	GENERAL NOTES	
A0.2	CODE ANALYSIS PLAN	
AD1.0	DEMOLITION PLAN	
AD3.0	EXTERIOR ELEVATIONS - DEMOLITION	
A1.0	NEW FLOOR PLAN	
A2.0	REFLECTED CEILING PLAN	
A3.0	EXTERIOR ELEVATIONS	
A3.1	INTERIOR ELEVATIONS	
A7.0	DOOR & HARDWARE SCHEDULES & DETAILS	
A7.1	ROOM SCHEDULE, FINISHES LEGEND & DETAILS	
A8.1	MILLWORK DETAILS	

ISSUED
FOR CONSTRUCTION

01/23/2021



WILLIAM STARCK
ARCHITECTS, INC.

126 COVE STREET
FALL RIVER, MASSACHUSETTS 02720
10 DORRANCE STREET, SUITE 700
PROVIDENCE, RHODE ISLAND 02903

OWNER: SOLAR THERAPEUTICS

1400 BRAYTON POINT ROAD
SOMERSET, MA 02725
T: (508) 300-3366

ARCHITECT: WILLIAM STARCK ARCHITECTS, INC.

126 COVE STREET
FALL RIVER, MA 02720
T: (508) 679-5733
F: (508) 672-8556

10 DORRANCE STREET, STE 700
PROVIDENCE, RI 02903


W: WWW.STARCKARCHITECTS.COM

MEP
ENGINEER:


DESIGN-BUILD

STRUCTURAL ENGINEER: C.A. PRETZER ASSOCIATES, INC.

50 FREEWAY DRIVE
CRANSTON, RI 02920
T: (401) 785-2690




1 NEW FLOOR PLAN
1/4" = 1'-0"



2 EXTERIOR WALL SECTION
1" = 1'-0"

KEYNOTES - FLOOR PLAN	
101	FURNISH AND INSTALL NEW FULL HEIGHT OPAQUE CHANNEL GLASS WALL, SIMILAR OR EQUAL TO PILKINGTON WAVE MODEL #256.0. EXTENTS OF CHANNEL GLASS WALL TO TERMINATE UNDER EXISTING ROOF JOISTS.
102	LIMITS OF NEW WALL CONSTRUCTION INFILL AT EXISTING WINDOW OPENING TO MATCH ADJACENT EXISTING WALL.
103	LIMITS OF NEW WALL CONSTRUCTION INFILL AT EXISTING DOOR OPENING TO MATCH ADJACENT EXISTING WALL.
104	NEW FRP PANELS MOUNTED 6'-0" AFF. ON 3 WALLS.
105	NEW WALL CONSTRUCTION INFILL TO ACCOMMODATE A KNOCK OUT PANEL FOR FUTURE DRIVE THRU WINDOW.
106	EXISTING MECHANICAL EQUIPMENT. NEW MECHANICAL WORK TO BE DESIGN BUILD BY OTHERS.
107	EXISTING ELECTRICAL EQUIPMENT. NEW ELECTRICAL WORK TO BE DESIGN BUILD BY OTHERS.
108	FURNISH AND INSTALL NEW ALUMINUM STOREFRONT SYSTEM. FOR ADDITIONAL INFORMATION REFER TO DWGS. A7.0& A7.1
109	NEW MILLWORK BY OTHERS, TYPICAL.
110	EXISTING STRUCTURAL COLUMN TO REMAIN. SCRAPE SAND AND OTHERWISE. PREPARE SUBSTRATE TO RECEIVE NEW PAINT FINISH (PRIMER COAT AND TWO FINISH COATS.)
111	NEW ADA COMPLIANT 1.28 GPF FLOOR MOUNTED, ONE-PIECE, CERAMIC GLAZED, WATER CLOSET. MODEL: ECO ULTRAMAX, BY TOTO. WHITE FINISH. INCLUDE SOFT CLOSE SEAT.
112	NEW ADA COMPLIANT WALL-MOUNT LAVATORY MODEL LT307 BY TOTO. FINISH: WHITE VITREOUS CHINA. CONCEALED ARM CARRIER. FITTING: ECOPOWER TEL-105 SERIES BY TOTO. INCLUDE 1 1/4" X 1 1/2" CAST BRASS TRAP WITH C.O. TRAP. INCLUDE OFFSET TAILPIECE AND TRUEBRO LAV GUAR.
113	NEW ADA COMPLIANT STAINLESS STEEL 22" X 19 1/2" X 5" SINGLE BOWL DROP-IN TYPE SINK. FITTING: K-596 BY KOHLER SIMPLICE INCLUDE 1 1/4 X 1 1/2" CAST BRASS TRAP WITH C.O. TRAP.
114	NEW ADA COMPLIANT FULLY RECESSED BOTTLE FILLING STATION. MODEL LZWSBK BY ELKAY.
115	NEW ALUMINUM TRANSITION STRIP AT DISSIMILAR FLOOR FINISH TRANSITIONS, BY SCHLITZER.
116	NEW SEMI-RECESSED FIRE EXTINGUISHER CABINET AND FIRE EXTINGUISHER. JL INDUSTRIES 1027VID VERTICAL DUO CLEAR ACRYLIC DOOR WITH COSMIC IDE FIRE EXTINGUISHER.
117	NEW FLOOR MOUNTED 24" X 20" X 11 1/4" 16 GA SS. MOP SINK BY ELKAY. FITTING: MAND. 3 1/2" P. TRAP. INCLUDE THE FOLLOWING BY FIAT: MOP HANGER MOL. # 889-CC. STRAINER MOL. #1453-BB. HOSE MDL. #832-AA. GUARD MDL. #E-77-AA.
118	



3 SILL PLATE DETAIL
1 1/2" = 1'-0"

FLOOR PLAN SYMBOLS	
	NEW DOOR; SEE DOOR SCHEDULE ON DWG. A7.0
	EXISTING WALL TO REMAIN
	NEW WALL CONSTRUCTION; SEE WALL TYPES ON DWG A0.1



WILLIAM STARCK ARCHITECTS, INC.
126 COVE STREET
FALL RIVER, MASSACHUSETTS 02720
10 DORRANCE STREET
PROVIDENCE, RHODE ISLAND 02903
TEL: 508.679.5733
FAX: 508.672.8556
WEB: WWW.STARCKARCHITECTS.COM



**SOLAR THERAPEUTICS
SEEKONK DISPENSARY**
1735 FALL RIVER AVENUE - SEEKONK, MA
02771

No.	Description	Date

SCALE: As indicated
DATE: 01/23/2021
DRAWN BY: BD/CA
PROJECT NUMBER: 20-204
DRAWING NAME

NEW FLOOR PLAN

DRAWING NUMBER

A1.0

COMMENTS
ISSUED FOR CONSTRUCTION

FINISH LEGEND						
SYM.	DESCRIPTION	MANUFACTURER	PRODUCT STYLE/COLOR	TEXTURE / FINISH	FLAME SPREAD SMOKE DEVELOPMENT	COMMENTS
ACT-1	ACOUSTIC CEILING TILE	ARMSTRONG	ULTIMA #1911; WHITE	BEVELED TEGULAR; FINE TEXTURE	CLASS-A	15/16" PRELUDE XL EXPOSED TEE GRID SYSTEM
ACT-2	ACOUSTIC LINEAR PLANK	GUSTAFS	PLAIN; LVS.NATURE VENEER; WALNUT	FINE TEXTURE	CLASS-A	
CP-1	CARPET TILE	MOHAWK GROUP	ENLIVENED; 958 ECRU	MONOLITHIC	CLASS 1 - ASTM E648 LESS THAN 450	
CP-2	WALK-OFF MAT	MATS INC.	BERBER	-	CLASS 1 - ASTM E648 LESS THAN 450	
CT-1	CERAMIC TILE - WALL	CROSSVILLE	COLOR BY NUMBERS; TEA FOR TWO	SATIN	-	
CT-2	CERAMIC TILE - WALL	CROSSVILLE	COLOR BY NUMBERS; NINE LIVES	SATIN	-	
CT-3	CERAMIC TILE - FLOOR	CROSSVILLE	BASALT; BEDROCK	UPS-UNPOLISHED	-	
LVT-1	LUXURY VINYL TILE	MOHAWK GROUP	MOLVENO STONES; 889 SOFTWARE	M-FORCE	PART A - ASTM E662 LESS THAN 450	
P-1	PAINT	SHERWIN WILLIAMS	SW 7636; ORIGAMI WHITE	EGG SHELL	-	
P-2	PAINT	SHERWIN WILLIAMS	SW 6279; BLACK SWAN	EGG SHELL	-	
P-3	PAINT	SHERWIN WILLIAMS	SW 6886; INVIGORATE	EGG SHELL	-	
P-4	PAINT	SHERWIN WILLIAMS	COLOR TO BE SELECTED BY ARCHITECT	SEMI-GLOSS	-	
P-5	PAINT	SHERWIN WILLIAMS	COLOR TO BE SELECTED BY ARCHITECT	SEMI-GLOSS	-	
PL-1	PLASTIC LAMINATE	FORMICA	TO BE SELECTED BY ARCHITECT	-	-	HORIZONTAL SURFACES - COUNTERTOP
PL-2	PLASTIC LAMINATE	FORMICA	COLOR TO BE SELECTED BY ARCHITECT	-	-	VERTICAL SURFACES - COUNTERTOP
RB-1	RUBBER BASE	MOHAWK GROUP	099; BLACK BROWN	STRAIGHT	-	
SS-1	SOLID SURFACE	ZODIAQ	TO BE SELECTED BY ARCHITECT	POLISHED	-	HORIZONTAL SURFACES - COUNTERTOP
ST-1	STAIN	SHERWIN WILLIAMS	CLEAR	SEMI-GLOSS	-	

ROOM FINISH SCHEDULE										
ROOM NO.	ROOM NAME	FLOOR	BASE	WALLS				CEILING	CEILING HEIGHT	REMARKS
				NORTH	EAST	SOUTH	WEST			
101	VESTIBULE	CP-2	RB-1	P-1	P-1	P-1	-	ACT-1	8'-0"	
102	RETAIL	*LVT-1 & CP-1	RB-1	P-1	P-1	P-1	P-3	P-2	EXISTING STRUCTURE	REFER TO A3.1 FOR MORE INFO.
103	SECURITY	LVT-1	RB-1	P-1	P-1	P-1	P-3	P-2	EXISTING STRUCTURE	*REFER TO A1.0 FOR MORE INFO.
104	OPEN AREA	*LVT-1 & CP-1	RB-1	P-1	P-1	P-1	P-1	ACT-1	8'-0"	*REFER TO A1.0 FOR MORE INFO.
105	SECURED STORAGE	CP-1	RB-1	P-1	P-1	P-1	P-1	ACT-1	8'-0"	
106	MANAGER OFFICE	CP-1	RB-1	P-1	P-1	P-1	P-1	ACT-1	8'-0"	
107	UTILITY CLOSET	CP-1	RB-1	P-1	P-1	P-1	P-1	ACT-1	8'-0"	
108	WOMEN	CT-3	-	P-1	CT-1/CT-2P-1	CT-1/CT-2P-1	CT-1/CT-2P-1	ACT-1	8'-0"	*REFER TO A3.1 FOR MORE INFO.
109	MEN	CT-3	-	CT-1/CT-2P-1	CT-1/CT-2P-1	P-1	CT-1/CT-2P-1	ACT-1	8'-0"	*REFER TO A3.1 FOR MORE INFO.

GENERAL WINDOW NOTES

- EXAMINE THE AREAS AND CONDITIONS UNDER WHICH WORK OF THIS TRADE WILL BE PERFORMED. CORRECT CONDITIONS DETRIMENTAL TO TIMELY AND PROPER COMPLETION OF THE WORK. DO NOT PROCEED UNTIL UNSATISFACTORY CONDITIONS HAVE BEEN CORRECTED.
- COORDINATE WITH OTHER TRADES TO ASSURE PROPER AND ADEQUATE PROVISION IN THE WORK OF THOSE TRADES FOR INTERFACE WITH THE WORK OF THIS TRADE.
- FIELD VERIFY ALL WINDOW OPENING DIMENSIONS PRIOR TO THE FABRICATION OF WINDOW UNITS. NOTIFY ARCHITECT OF ANY DISCREPANCIES. DO NOT DELAY JOB; ALLOW FOR ON-SITE CUTTING AND FITTING IF OBTAINING FIELD MEASUREMENTS IS NOT PRACTICAL.
- CUT, REINFORCE, DRILL AND TAP WORK AS REQUIRED TO RECEIVE HARDWARE AND SIMILAR ITEMS.
- PROVIDE FASTENERS, ANCHORS, SHIMS, SETTING BLOCKS, SEALANTS AND ANY OTHER MATERIALS NOT SPECIFICALLY DESCRIBED BUT REQUIRED FOR A COMPLETE INSTALLATION.
- PERFORM INSTALLATION IN ACCORDANCE WITH THE MANUFACTURER'S INSTRUCTIONS EXCEPT WHERE MORE STRINGENT REQUIREMENTS ARE SHOWN AND EXCEPT WHERE PROJECT CONDITIONS REQUIRE EXTRA PRECAUTIONS OR PREVISIONS TO ENSURE SATISFACTORY PERFORMANCE OF THE WORK.
- WINDOW SYSTEM IS BASED ON KAWNEER 451T TRIFAB SYSTEM OR APPROVED EQUAL.
 - IF NOT NOTED OTHERWISE, ALL EXTERIOR GLAZING IS TO BE 1" LOW E INSULATED CLEAR GLASS. INTERIOR GLAZING TO BE 1/4" PLATE GLASS WITH TEMPERED GLASS PANELS LOCATED AS SHOWN ON DRAWINGS. PANELS REQUIRED TO BE TEMPERED ARE INDICATED BY (T).
- ALL FRAMING MEMBERS TO BE FACTORY FINISHED IN COLORS SPECIFIED. EXTERIOR FRAMES INDICATED TO BE COLOR, SHALL BE KYNAR 500 OR 700.
- INSTALL STONE WOOL INSULATION IN ALL VOIDS AT WINDOW PERIMETER INCLUDING STUD POCKETS AND UNDER ALL SILLS.

FINISH NOTES


- PROVIDE PRIMERS AND UNDERCOATS BY SAME MANUFACTURER OF FINISH COAT. USE ONLY THINNERS APPROVED BY PAINT MANUFACTURER AND USE ONLY WITHIN RECOMMENDED LIMITS.
- PROVIDE THE FOLLOWING PAINT SYSTEMS BASED ON SUBSTRATE MATERIALS:
 - GYPSUM DRYWALL WALLS/CEILINGS/SOFFITS:
EGGSHELL ACRYLIC-ENAMEL FINISH:
TWO COATS OVER PRIMER
2.1.1. PRIMER: INTERIOR GYP. BD. PRIMER.
2.1.2. FINISH COATS: INTERIOR EGGSHELL ACRYLIC ENAMEL.
 - INTERIOR METAL FRAMES AND METAL TRIM:
SEMI GLOSS ACRYLIC-ENAMEL FINISH:
TWO COATS OVER A PRIMER
2.2.1. PRIMER: INTERIOR FERROUS-METAL PRIMER.
2.2.2. FINISH COATS: INTERIOR SEMI GLOSS ACRYLIC ENAMEL.
- ALL FINISHES SHALL BE INSTALLED IN STRICT ACCORDANCE WITH MANUFACTURERS WRITTEN INSTRUCTIONS.
- PROVIDE VINYL STRAIGHT BASE AT CARPETED FLOORS.
- PAINT EXPOSED ELECTRIC PANELS (2 COATS BEFORE MOUNTING), EXPOSED ELECTRICAL RACEWAYS, BOXES AND FITTINGS.
- PROVIDE TRANSITION STRIPS AT JUNCTION OF DISSIMILAR FLOORING MATERIALS. IF NOT OTHERWISE NOTED, PROVIDE VINYL STRIPS AT JUNCTION OF CARPET AND VINYL, AND METAL STRIPS (SCHLUTER, OR EQUAL, AT JUNCTION OF TILE FLOORS. SUBMIT PRODUCT DATA AND SAMPLES FOR COLOR SELECTION.
- TILE SHALL BE THINSET WITH UNSANDED GROUT.
- SUBMIT SAMPLES OF ALL COLORS ON VARIOUS SUBSTRATE MATERIALS SPECIFIED ON DRAWINGS, AS WELL AS ANY COLOR SUBSTITUTIONS REQUESTED BY OWNER, UNTIL FINAL APPROVAL OF PAINT AND STAIN COLORS IS OBTAINED.




WILLIAM STARCK ARCHITECTS, INC.
 126 COVE STREET
 FALL RIVER, MASSACHUSETTS 02720
 10 DORRANCE STREET
 PROVIDENCE, RHODE ISLAND 02903
 TEL: 508.879.5733
 FAX: 508.672.8556
 WEB: WWW.STARCKARCHITECTS.COM




**SOLAR THERAPEUTICS
 SEEKONK DISPENSARY**
 1735 FALL RIVER AVENUE - SEEKONK, MA
 02771




1 WINDOW TYPE - A
 1/2" = 1'-0"




2 WINDOW TYPE - B
 1/2" = 1'-0"



3 WINDOW TYPE - C
 1/2" = 1'-0"



4 WINDOW JAMB DETAIL - CMU WALL
 1 1/2" = 1'-0"



5 WINDOW JAMB DETAIL
 1 1/2" = 1'-0"

No.	Description	Date

SCALE: As indicated
 DATE: 01/23/2021
 DRAWN BY: BD/CA
 PROJECT NUMBER: 20-204

DRAWING NAME
**ROOM SCHEDULE,
 FINISHES LEGEND &
 DETAILS**

DRAWING NUMBER

A7.1

COMMENTS
 ISSUED FOR CONSTRUCTION

Cannabis Control Commission
Union Station
2 Washington Square
Worcester, MA 01604

To:

We are pleased to provide the commission with documentation and our approach to energy compliance. Solar Therapeutics has reviewed all civil designs and construction plans for our Solar Therapeutics Seekonk Dispensary located at 1735 Fall River Ave., Seekonk, MA 02771.

Please see the attached document that has been certified by William Starck Architects, a Massachusetts Licensed Registered Architect. License #3643 by the Massachusetts Board of Registration of Architects.

All designs and construction are in accordance with building regulations and standards set forth within:

- 2018 International Energy Conservation Code (IECC).
- 2018 IECC Massachusetts amendments
- 780 CMR 9th ed.- Massachusetts Building Code (IBC 2015)

Additionally, all designs and construction are in accordance with all Seekonk Building Department and Seekonk Zoning & Planning Department codes and specifications.

Wherever possible, multiple strategies are being employed to reduce energy demand including using all energy-efficient LED lighting and high-efficiency HVAC equipment. As a sustainability-first operator, our dispensaries operate in a dimmed, low-light atmosphere to reduce energy consumption.

Attached to this letter you will find:

- 2021_0123 Solar Therapeutics - Seekonk Dispensary Final CD's Issued

If you have any questions or need additional information, please feel free to contact us.

Thank you,

Seekonk/Dartmouth/Somerset Overview

Solar Therapeutics, Inc. ("Solar Cannabis Co.") is dedicated to promoting equity in its operations for diverse populations, which the Commission has identified as the following:

1. Minorities;
2. Women;
3. Veterans;
4. People with disabilities; and
5. LGBTQ+

To support such populations, Solar Cannabis Co. has created the following Diversity Plan (the "Plan") that will work in conjunction with its Positive Impact Plan and has identified and created goals/programs to promote equity in Solar Cannabis Co's operations.

Goals

In order for Solar Cannabis Co. to promote equity for the above-listed groups in its operations, Solar Cannabis Co. has established the following goals:

1. Increasing the number of individuals falling into the above-listed demographics working in the establishment by using best efforts to hit or exceed the following demographic mix for individuals:
 - 50% Women
 - 30% Racial Minorities
 - 15% Veterans
 - 15% Persons with Disabilities
 - 15% LGBTQ+
2. Providing tools to ensure the success of individuals falling into the above-listed demographics.

Actionable Items:

To help encourage a more diverse employee population, Solar Cannabis Co. currently utilizes an integrated Applicant Tracking System (ATS) where applicants can voluntarily self-identify (race, gender and Veteran status) or they have the option to opt out. The ATS also allows Solar Cannabis Co. to identify geographic locations with high minority populations to actively recruit in those areas (eg. job fairs, educational seminars, high-level training, etc.).

Programs

Solar Cannabis Co. has developed specific programs targeted at its designated areas of disproportionate impact on the Southcoast to effectuate its stated goals to promote diversity and equity in its operations, which will include the following:

Economic Empowerment Hiring and Mentorship:

Solar Cannabis Co. will collaborate with city-specific Departments of Economic and Community Development, Bristol Community College and MassEON to hold live educational seminars that will discuss employment within the cannabis industry. Solar will also utilize this program to hold a job fair to the aforementioned communities and allow them the opportunity to network with various department heads within the organization. This seminar will also provide overviews on employment and offer high-level training collateral pertaining to marijuana cultivation, marijuana product and manufacturing, marijuana retailing and marijuana business. The workshop will be advertised throughout those designated areas traditional media outlets, as well as leveraging paid targeted social media advertisements.

Veteran & Disabled Veteran Engagement Hiring and Mentorship:

Solar Cannabis Co. will collaborate with city-specific Departments of Veterans Services and Bristol Community College to co-host educational seminars that would allow all qualified Veterans within the area the opportunity to learn more about the cannabis industry and potential careers and ways to access assistance and tools for workforce development. This seminar will provide overviews on employment and offer high-level training collateral pertaining to marijuana cultivation, marijuana product and manufacturing, marijuana retailing and marijuana business. The workshop will be advertised throughout those designated areas traditional media outlets, as well as leveraging paid targeted social media advertisements.

LGBTQ+ Inclusivity Hiring and Mentorship:

Solar Cannabis Co. will collaborate with the city-specific Departments of Economic and Community Development, Boston GLASS and Bristol Community College to hold educational workshops that will aim to educate those within the local LGBTQ+ community about the cannabis industry as a whole and various ways to get involved in the legal Massachusetts marijuana industry. This seminar will provide overviews on employment and offer high-level training collateral pertaining to marijuana cultivation, marijuana product and manufacturing, marijuana retailing and marijuana business. The workshop will be advertised throughout those designated areas traditional media outlets, as well as leveraging paid targeted social media advertisements.

Measurements

The Chief Operating Officer (“COO”) will administer the Plan and will be responsible for developing measurable outcomes to ensure Solar Cannabis Co. continues to meet its commitments. Such measurable outcomes, in accordance with Solar Thera’s goals and programs described above, include:

- Counting the number of individuals hired who are women, minorities, and persons with disabilities. This number will be assessed from the total number of individuals hired to ensure that 50% of all individuals hired fall within this goal.
- Number of positions created since initial licensure;

- Number of and type of information sessions held or participated in with supporting documentation;
- Number of postings in diverse publications or general publications with supporting documentation;
- Number and subject matter of trainings held and the number of individuals falling into the above-listed demographics in attendance; and
- A comprehensive description of all efforts made by Solar Cannabis Co. to monitor and enforce the Plan.

The COO will review and evaluate Solar Cannabis Co. measurable outcomes no less than annually to ensure that Solar Cannabis Co. is meeting its commitments. Solar Cannabis Co. is mindful that demonstration of the Plan's progress and success will be submitted to the Commission upon renewal.

Acknowledgements

Solar Cannabis Co. will adhere to the requirements set forth in 935 CMR 500.105(4) which provides the permitted and prohibited advertising, branding, marketing, and sponsorship practices of every Marijuana Establishment.

Any actions taken, or programs instituted, by Solar Cannabis Co. will not violate the Commission's regulations with respect to limitations on ownership or control or other applicable state laws.